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Introduction: Off-label (OL) medicine use in children is a common practice not yet extensively 
investigated in Africa. 
Aim: The aim of the study was to determine the extent of unregistered (UR) and OL medicine use 
in inpatients admitted to highly specialised paediatric wards at a tertiary hospital in South Africa.  
Objectives: The primary objective of the study was to determine the frequency of UR and OL 
medicine events in highly specialised paediatrics. The secondary objective was to determine the most 
frequently prescribed UR and OL medicines per paediatric subspecialty.  
Respondents and methods: This was a prospective descriptive study over a period of three months 
(October to December 2011), documenting all medicines prescribed to children (under 18 years) 
admitted for highly specialised inpatient care to Tygerberg Hospital in Parow, Cape Town. Patients 
were classified into four age groups: newborns (0–27 days), infants (28 days to 23 months), children 
(2–11 years) and adolescents (12–18 years). Data collected included demographic data, diagnostic 
data and data concerning all medicine events. Data analysis of medicine events included registration 
status (defining extemporaneous use as UR use) and OL use according to dose, frequency, route of 
administration, age and indication.  
Results: There were 1 514 medicine events for 199 children (mean age?; range), with an average of 
7 medicines per child (range 1–28). The majority of the medicine events were in the age category 
infants (44%), followed by children (42%), adolescents (8%) and neonates (6%). Nearly half (49%) 
of all the medicine events were either UR (20%) or OL (29%). Almost a quarter (22%) of the patients 
received a UR medicine, 68% an OL medicine and 24% both a UR and an OL medicine. The most 
common reason for OL medicine use was dose for weight (22.2%), while extemporaneous use as 
UR use involved 5% of all medicine events. Extemporaneous use (23%) and OL use (42%) were 
particularly common in paediatric infectious diseases, especially for antituberculosis medicines, 
reflecting the burden of paediatric disease due to tuberculosis and also confirming that few of these 
medicines have been tested in children. 
Conclusions: OL and UR medicine use is common in highly specialised paediatrics in South Africa, 
especially for children with infectious diseases. The findings indicate the need for dedicated 
paediatric clinical trials in South Africa to establish safety and efficacy data, especially to improve 
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paediatric medicine formulations.  
 
 





Inleiding: Die gebruik van niegoedgekeurde (NG) medisyne by kinders is ŉ algemene praktyk wat 
nog nie uitvoerig in Afrika ondersoek is nie. 
Oogmerk: Die oogmerk van die studie was om die omvang te ondersoek van die gebruik van 
ongeregistreerde (OR) en NG medisyne by hospitaalpasiënte wat in hoogs gespesialiseerde 
pediatriese sale by ŉ tersiêre hospitaal in Suid-Afrika opgeneem is.  
Doelstellings: Die primêre doelstelling van die studie was om die frekwensie van gebeure rakende 
OR en NG medisyne in hoogs gespesialiseerde pediatrie te bepaal. Die sekondêre doelstelling was 
om te bepaal watter OR en NG medisyne die gereeldste per pediatriese subspesialiteit voorgeskryf 
word.  
Respondente en metodes: Hierdie studie was ŉ prospektiewe beskrywende studie oor ŉ tydperk van 
drie maande (Oktober tot Desember 2011), waarin alle medisyne wat voorgeskryf is aan kinders 
(jonger as 18 jaar) wat vir hoogs gespesialiseerde hospitaalsorg by Tygerberg Hospitaal in Parow, 
Kaapstad, opgeneem is, opgeteken is. Pasiënte is in vier ouderdomsgroepe geklassifiseer: 
pasgeborenes (0–27 dae), babas (28 dae tot 23 maande), kinders (2–11 jaar) en adolessente (12–18 
jaar). Data wat ingesamel is, het ingesluit demografiese data, diagnostiese data en data oor alle 
medikasiegebeure. Data-ontleding van medikasiegebeure het ingesluit registrasiestatus (waarin 
geïmproviseerde gebruik as OR gebruik gedefinieer is) en NG gebruik volgens dosis, frekwensie, 
toedieningsmetode, ouderdom en indikasie.  
Resultate: Daar was 1 514 medikasiegebeure vir 199 kinders (gemiddelde ouderdom?; bestek), met 
ŉ gemiddelde van 7 medisynes per kind (bestek 1–28). Die meerderheid medikasiegebeure was in 
die ouderdomskategorie van babas (44%), gevolg deur kinders (42%), adolessente (8%) en 
pasgeborenes (6%). Bykans die helfte (49%) van al die medikasiegebeure was óf OR (20%) óf NG 
(29%). Byna ŉ kwart (22%) van die pasiënte het OR medisyne ontvang, 68% NG medisyne en 24% 
sowel OR as NG medisyne. Die algemeenste rede vir die gebruik van NG medisyne was dosis vir 
gewig (22.2%), terwyl geïmproviseerde gebruik as OR gebruik by 5% van alle medikasiegebeure 
betrokke was. Geïmproviseerde gebruik (23%) en NG gebruik (42%) was veral algemeen by 
pediatriese aansteeklike siektes, veral vir antituberkulose-medisyne, wat die las van pediatriese 
siektes weens tuberkulose weerspieël en ook bevestig dat min van hierdie medisyne by kinders 




Gevolgtrekkings: Die gebruik van NG en OR medisyne is algemeen in hoogs gespesialiseerde 
pediatrie in Suid-Afrika, veral by kinders met aansteeklike siektes. Die bevindinge dui op die 
behoefte aan toegewyde pediatriese kliniese toetse in Suid-Afrika om veiligheids- en 
doeltreffendheidsdata te verkry, veral om pediatriese medisyneformulering te verbeter.  
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Adolescent: Paediatric patient aged older than 11 and younger than 18 years, defined as used in 
study.53 
Adverse medicine reaction: A noxious and unintended response to a medicine that occurs at normal 
therapeutic doses used in humans for prophylaxis, diagnosis or therapy of disease, or for the 
modification of physiologic function.12 
AIDS: Acquired immunodeficiency syndrome. 
Central/tertiary hospitals: Hospitals in South Africa that provide both general specialist services and 
highly specialised (Level 3) services.54 
Child: Paediatric patient aged 2–11 years, defined as used in study.53  
Excipients: Inactive pharmaceutical ingredients utilised in extemporaneous medicine 
compounding.26 
 
Extemporaneous compounding: Refers to the manipulation or compounding of a manufactured 
medicine (crushing of tablets or opening of capsules and suspending the contents in fluid), resulting 
in a change in the form or properties of the manufactured medicine, or the manufacturing of a 
medicine from raw products by a production pharmacist.26 
Highly specialised paediatrics: Medical care provided to children by subspecialist paediatricians. 
HIV: Human immunodeficiency virus.  
HAART: Highly active antiretroviral therapy. 
Infant and toddler: Paediatric patient older than 27 days and younger than 2 years.53  
Manipulation: Breaking a tablet or splitting a capsule at the time of administration, a subcategory of 
extemporaneous compounding.26 
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Medicine: Any pharmacological agent prescribed and administered to a patient; this excludes 
intravenous fluid therapy and blood transfusions.  
Medicine event: A single prescription of an individual medicine on a prescription chart of a patient. 
Medicines Control Council: The national regulatory body for medicine registration. 
Neonate: Paediatric patient aged 0–27 days.53 
Off-label (OL) medicine: Medicine prescribed outside the terms and conditions of the product 
license.47 
Pharmacodynamics: The study of the effects of medicine on the body. 
Pharmacokinetics: The study of the mechanism by which a medicine is absorbed, distributed, 
metabolised and eliminated by the body. 
Regional hospitals: Hospitals in South Africa that provide general specialist care (Level 2) services.54 
 
Special formulations: These are medicines already registered in one form but reformulated under a 
special license to meet the therapeutic needs of a patient. 
Subspecialist: A paediatrician who has further specialised in a particular clinical area of paediatrics. 
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Chapter 1: Introduction 
1.1 Background and context 
The registration of medicines is overseen by national regulatory systems, which in South Africa is 
the Medicines Control Council (MCC).1,2 These regulatory bodies ensure that medicines are tested 
for safety, efficacy and quality prior to public marketing and utilisation.3,4 The gold standard for adult 
medicine is the proven safety and efficacy data generated through adequate clinical trials.5 
Unregistered (UR) medicine use refers to a medicine that is prescribed but not registered with the 
national regulatory system, while off-label (OL) medicine use refers to the practice of prescribing a 
registered medicine outside of the conditions for which it is registered.2 OL medicine use can pertain 
to age, dose, formulation, route, frequency or not being registered for a specific indication.6 OL and 
UR medicine use is common in paediatric medicine, especially neonatology and paediatric critical 
care.7 This practice is raising concern globally, as documented in studies from Europe, the United 
States of America (USA) and Brazil,8 as up to 75% of medicines prescribed to children worldwide 
are OL.9 OL and UR medicine use may offer therapeutic benefit, may have no therapeutic effect or 
may result in adverse medicine events.10 The documented increased risk of adverse medicine 
events11,12,13,14 and medication errors15 with OL medicine use is a cause for concern. However, 
clinicians’ reluctance to prescribe a UR or an OL medicine may also deprive a child of potentially 
effective treatment.10 
 
The practice of prescribing UR or OL medicine is due to a lack of paediatric-specific scientific data 
derived from clinical trials to satisfy the national registering requirements with regard to efficacy 
and safety.5 Such utilisation is not always inappropriate and may be justified within a specific clinical 
context.5 For example, in paediatric oncology, the OL and UR use of medicines and biological 
products forms an essential part of many internationally standardised treatment protocols.16 
Similarly, in paediatric cardiology, the first-line treatment for maintaining ductal patency in duct-
dependent congenital cyanotic heart lesions is prostaglandin.17 In autoimmune and inflammatory 
central nervous system disorders, the OL use of rituximab was demonstrated to improve neurological 
outcomes.18 Other considerations that need to be taken into account are prescriber awareness, 
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litigation fears, parental and child awareness, and the risk-benefit ratio based on the clinical 
indication when medicines are prescribed OL.19,20 With this study, we wanted to determine the extent 
of OL and UR medicine use in highly specialised paediatrics in a single central/tertiary hospital in 
South Africa, as there is a paucity of published data from Africa.  
  
1.2 Literature review 
Licensing ensures that medicines are tested in rigorous clinical trials for safety, efficacy and quality 
prior to public use.21 Pharmacotherapeutic tragedies that exposed children to the adverse effects of 
inadequately studied medicines prompted the development of medicine regulation.1 In 1901, for 
example, diphtheria toxoid contaminated with tetanus resulted in the deaths of 13 children.22 OL use 
of the sedative thalidomide in the first trimester of pregnancy for pregnancy-induced vomiting 
resulted in miscarriages, stillborn infants and multiple birth defects, including phocomelia.23 
Historically, chloramphenicol administered to neonates resulted in grey baby syndrome.24 The 
characteristic grey discolouration, cyanosis, vomiting, acidosis and hypothermia were due to age-
related deficiency in glucuronide conjugation, the main pathway for chloramphenicol excretion. 
These complications can be prevented with lower doses administered, decreased frequency of 
medicine administration and therapeutic medicine monitoring.24 Diethylene glycol, a diluent used in 
the manufacturing of elixirs, has resulted in the deaths of children on more than one occasion.24 In 
1937, 34 children succumbed to toxicity-related adverse reactions. This tragedy repeated itself in 
Nigeria (1990 and 2009), Bangladesh (1990 and 1992) and Haiti (1995 and 1996).24 Most recently 
in 2011, lopinavir/ritonavir use in premature infants exposed them to ethanol/propylene toxicity.9 
Due to these adverse events, medicine safety communication resulted in a change in 
lopinavir/ritonavir labelling in 2011.9  
 
Children have been referred to as ‘therapeutic orphans’ as a large number of medicines utilised in 
the clinical management of children are lacking in scientific evidence to support their paediatric 
use.21 The growing global concern about this matter is evidenced by the growing number of studies 
documenting the extent of UR and OL medicine use.8,11,25 Globally up to three-quarters (40–60%) 
of medicines used in children in the European Union (EU) and two-thirds in the USA are used 
OL.7,8,9 




The definitions of UR and OL medicine use differ widely in the literature, making direct comparisons 
among various studies difficult.7 According to Conroy et al5 and Turner et al,26 a UR medicine is a 
medicine that has not received marketing authorisation, while OL medicine utilisation refers to the 
use of a medicine outside the terms of the product registration. The authors categorise 
extemporaneous preparations, formulations manufactured under a special license and medicines 
without a stated dose for a particular age group as UR medicines.6 Extemporaneous compounding is 
the process whereby a manufactured product is manipulated or compounded into a different 
formulation or a new product is manufactured from raw ingredients in a manufacturing pharmacy.26 
Extemporaneously compounded medicines can be categorised as UR medicine use as compounding 
of medicines removes the regulatory safeguards, unless such manipulation or compounding is 
specifically covered in the product’s package insert.27 Medicines that are extemporaneously 
compounded or manipulated are not subjected to the regulatory safeguards that ensure the quality, 
safety and efficacy of the specified use during the registration process; therefore, prescribers and 
pharmacists cannot make assumptions about the quality, safety and efficacy of these medicines.28 
Consensus on the definition of these terms for utilisation for research and regulatory purposes was 
recently reached through a Delphi survey.6 According to this survey, extemporaneously compounded 
medicines and medicines manipulated at the time of administration are classified as OL medicines.6  
 
OL and UR medicine use is common in all paediatric clinical settings, including neonatal and 
paediatric intensive care units, paediatric inpatients, emergency paediatrics and ambulatory 
paediatrics.4 Several systematic reviews,7,8,25 multicentre studies29,31 and single-centre30 studies have 
evaluated the extent of UR and OL medicine use in different clinical settings (paediatric wards, 
intensive care units, ambulatory care and primary health care).7,8,25-31,35 OL medicine use ranged 
from 7% to 70% of paediatric medicine events,7,8,25,35 while UR medicine use ranged from 0.2% to 
48%.8,25,35 The percentage of children exposed to an OL or a UR medicine event ranged from 42% 
to 100%.8 The main reason for OL use was dose,7,8,30,35 followed by age,7,8,30 lack of paediatric data,8 
frequency and formulation.35 These findings were confirmed by recent studies (last five years) 
documenting UR and OL medicine use in hospitalised children in Australia,32 Finland,33 Croatia10 
and Palestine.34 The study designs varied from retrospective32 to prospective studies33,34 and included 
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one cross-sectional survey.10 Consistent among all these studies was that OL medicine use (13.3–
71%) was more common than UR medicine use (2.6–35.3%)10,32,34 and that the most common 
reasons for OL medicine use were dose and age, especially in neonates and young children.10,32-34  
 
Younger children, especially neonates, were subjected to the highest percentage of UR and OL 
medicine events.7,8 The number of neonates exposed to at least one OL or UR medicine ranged from 
80% to 100% versus 32% to 62% for children.7 The most common subgroups of medicines used OL 
in neonates, according to the World Health Organization (WHO) Anatomical Therapeutic Chemical 
(ATC) classification system, were cardiovascular medicines, anti-infectives for systemic use and 
medicines acting on the central nervous system.7,8,25,30,31 In neonatal critical care, the proportion of 
medicine events that were UR ranged from 10% to 62% and for OL use from 14% to 63%.36,37,38  
 
Conroy et al conducted a prospective multicentre international survey of paediatric wards in five 
European countries and found that nearly half of all medicine events (46%) were either UR or OL 
(7.3% UR; 38.5% OL).35 The most common reasons for OL medicine use were dose, frequency and 
formulations. Paracetamol was the most frequently prescribed medicine in most of the centres, while 
the most frequently used OL medicines differed widely among centres, including the following: 
paracetamol, salbutamol, budesonide, beclometasone and cyclizine.35 
 
An investigation of UR and OL medicine use in paediatric pain management in a prospective study 
found that paracetamol was the most frequently used analgesic and accounted for 40% of medicine 
events, followed by brufen (20%) and codeine phosphate (11%).39 Diclofenac, pethidine and 
morphine each accounted for 7% of medicine events. All the medicine events for pethidine (100%), 
98% for diclofenac, 79% for morphine and 30% for paracetamol were OL.39 The most common 
reason for OL use was dose (12%). OL use for route, age and indication each accounted for 7% and 
weight for 1% of medicine events.39 
 
The clinical trials evaluating the OL use of omalizumab, a recombinant DNA-derived monoclonal 
antibody registered for the treatment of moderate and severe persistent asthma and chronic 
spontaneous uticaria in adults and children (more than 6 years in the EU and more than 12 years in 
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the USA), found it to be efficacious and well tolerated for the treatment of seasonal allergic rhinitis, 
with efficacy being enhanced when combined with subcutaneous immunotherapy as example of OL 
use for indication.40 Treatment for other OL indications such as allergic broncho-pulmonary 
aspergillosis, nasal polyps, severe refractory atopic dermatitis, and food allergy and anaphylaxis is 
currently not supported by paediatric literature, despite growing popularity of the OL use of this 
medicine.40 
 
Published data on the extent of UR and OL medicine use in developing countries and sub-Saharan 
Africa is limited. In Nigeria, nearly half (41.9%) of the medicines prescribed to children aged 0–5 
years in a tertiary and a primary health care centre were UR and OL. Overall, one-fifth (20.4%) of 
medicine events were either UR or OL (21.5%).41 OL medicine use was more frequent in the tertiary 
health care centre (24%) compared to the primary health care centre (18.7%), while UR medicine 
use was more common in the primary health care centre (27.5%) compared to the tertiary health care 
centre (13.9%).41 The most common reason for UR medicine use was extemporaneously prepared 
medicines, while dose was the most common reason for OL medicine use.41 The most frequently 
used ATC classification medicine subclasses were antibacterial agents, antiprotozoal agents, 
analgesics, vitamins and haematopoietic medication in both centres, which correlates with the profile 
of diseases treated most frequently, namely malaria and other infectious diseases (respiratory tract 
infections, gastroenteritis, sepsis and HIV/AIDS) that can present with pyrexia and anaemia.41 
Paracetamol use accounted for 12.1% of all medicine events, although the exact frequency of UR 
and OL use of individual medicines was not reported. A limiting factor of this study was the 
retrospective nature and insufficient patient medical, medication and demographic data.41 
  
Although there are reports of UR and OL use of specific medicines in South Africa, published data 
on the extent of UR and OL medication in the different clinical settings is lacking. A survey of 
intravenous immunoglobulin use at a tertiary paediatric health care centre found that more than half 
the intravenous immunoglobulin utilisation (59%) was OL for indication.42 The most frequent 
clinical indications for OL use were infections and post organ transplant.42 OL medicine use was 
most frequent in children aged more than five years, accounting for nearly half (46%), followed by 
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children aged less than a year (29%), while those aged 1–5 years accounted for a quarter (25%) of 
OL medicine events.42  
 
Dinoprostone (prostaglandin E2 receptor agonist) is registered in South Africa for the induction of 
labour but is used OL to provide lifesaving emergency treatment by maintaining ductal patency when 
administered to newborns suffering from duct-dependent congenital cyanotic cardiac lesions, as well 
as long-term treatment of low-birth-weight infants with duct-dependent pulmonary circulations not 
yet meeting the criteria for corrective shunt surgery.17 In 2009, no warning was given to clinicians 
about the national shortage of this lifesaving medicine in both the public and the private sector, due 
to legislative constraints as the medicine is not registered for such use.17 This led to a serious shortage 
of this lifesaving medicine, proving the necessity to conduct clinical trials to ensure registration of 
this medicine for this indication in South Africa.17  
 
Children have specific therapeutic needs that need to be addressed as they are not small adults.9 
Extrapolation of data from adults to children is not possible due to age-related differences in 
physiology and disease pathophysiology.22 Children demonstrate physiological variations in 
pharmacokinetics and pharmacodynamics corresponding to the different developmental stages of 
childhood. These factors affect the absorption, distribution, metabolism and excretion of medicines. 
Significant dose adjustments may be required to target similar plasma concentrations as in adults.3 
It is therefore necessary to ensure that scientifically based age-related dosing information is available 
as treatment failure can result from subtherapeutic doses and adverse effects without any therapeutic 
benefit from doses higher than required.32 
 
Children also require medicine formulations that are appropriate for the developmental age of the 
child, and medicine palatability is an especially important factor in children.9 Palatability may affect 
adherence and subsequently treatment outcome.9 It is common practice, due to the unavailability of 
suitable age-appropriate formulations, for medicines to be prepared extemporaneously 
(compounding medication from ingredients within a pharmacy), or the dose, form or route of a 
medicine may be manipulated. This practice raises safety concerns, and efficacy may be 
compromised.9 There is an environmental risk, especially with the handling of cytotoxic and 
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biological medicines, and an individual occupational risk for the health care provider.9 Manipulated 
medicines and extemporaneous preparations are not well supported by pharmacokinetic and 
pharmacodynamic data, nor is there sufficient data to validate tolerability, stability and 
reproducibility. These factors make medicine use in this manner unsafe.9 
 
Clinical trials are the gold standard to generate scientific data to support a medicine’s safety profile, 
efficacy and quality prior to registration, public marketing and use.3 Conducting clinical trials in the 
paediatric subpopulation is, however, challenging, especially due to children’s vulnerability.3 
Reasons for the lack of paediatric clinical trials include the small commercial market for children, 
the lower projected commercial gains, as well as litigation fears.3 There are also ethical concerns, 
especially related to possible harm, the complex consent process including parental consent as third-
party consent and smaller numbers of participants.3 
 
The risk of adverse medicine reactions11-13,26 and medication errors15 is increased with UR and OL 
medicine use.11-13,15,26 According to the WHO, an adverse medicine reaction is defined as “an effect 
that is noxious and unintended, and which occurs at doses used in man for prophylaxis, diagnosis 
and therapy”.12 Neubert et al reported that the overall incidence of adverse medicine reactions was 
17.4%,12 while Turner et al found it to be 9.9%.26 The incidence of an adverse medicine event 
associated with UR and OL medicine use was 6% respectively in both studies, compared to that of 
adverse medicine events associated with registered medicine use at 5.6% (Neubert et al)12 and 3.9% 
(Turner et al).26 Bellis et al11 and Santos et al43 found that the relative risk of an adverse medicine 
reaction was increased 1.67 fold and 2.4 fold for a UR or an OL medicine course respectively 
compared to a registered medicine.11,43 The other safety concern is the association of registration 
status with medication errors (prescribing, dispensing, labelling or administration). Conroy et al 
found that compared to registered medicine use, a UR medicine was more likely to be associated 
with errors.15 The error rate was higher in neonatal wards (38%), and the risk of a medication error 
was increased 5.8 fold compared to the error rate in paediatric wards (17%), with a 2.2-fold increased 
risk of a medication error.15 The degree of harm caused by the medication error was graded according 
to the United Kingdom (UK) National Patient Safety Agency definitions, with more than half (60%) 
of the medication errors causing moderate harm being associated with UR (25%) or OL medicine 
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(35%) use.15 Medication errors that caused moderate harm were 2.8 times more likely to be 
associated with a UR and an OL medicine compared to a registered medicine. No medication errors 
caused severe harm or death.15 
 
 The views of children and health care providers’ experiences with and attitudes towards UR and OL 
prescribing and paediatric clinical trials are important. Mukkattash et al reported that healthy school 
children aged 10–16 years in focus group discussions were of the opinion that UR and OL medicine 
use was unsafe and unethical and advocated for medicine testing to assist in the licensing of 
medicines for children.44 Health care providers expressed familiarity with UR and OL medicine use, 
mainly through personal experience. Despite safety and efficacy concerns in the majority, only 30% 
of practitioners informed parents about their safety and efficacy concerns, 56% believed that clinical 
trials were necessary for medicine evaluation and only 28.3% were willing to be part of clinical 
research.44 
 
Due to the overwhelming evidence and documentation of the extent of UR and OL medicine use, 
legislators in the USA and Europe have implemented paediatric regulations in an effort to improve 
the development of safe and effective medication for children.24,45 The USA has led this effort with 
two significant outcomes resulting from multiple legislation and policy amendments: The first action 
taken was a six-month extension of patency (Food and Medicine Modernisation Act, 1997 and Best 
Pharmaceuticals for Children’s Act [BPCA], 2002), and the second action was the mandatory 
provision of paediatric data and labelling instructions by pharmaceutical companies for new 
medicines, biological, addition of new indications, dose forms and regimens for any medicine with 
the potential for paediatric use (Pediatric Research Equity Act [PREA], 2003).24 The BCPA and 
PREA were reinstated in 2007 as part of the Food and Drug Administration Amendments Act, 
2007.24 Europe has also implemented legislative changes.46 The European Commission enacted the 
EU Paediatric Regulation 1901/2006 on medicinal products for paediatric use.46 Pharmaceutical 
companies are now required to submit a Paediatric Investigation Plan, and as reward they will be 
granted a six-month extension of the medicine patent. The European aim is to generate paediatric 
data without exposing children to unnecessary clinical trials or delaying the registration of adult 
medicines.46   
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Legislative changes have had an impact on UR and OL medicine use in children. Osuagu et al 
compared prelegislation OL and UR medicine use (2001) to postlegislation OL and UR medicine 
use (2011).33 The overall percentage of UR medicine use remained stable at 13%, but there was 
an increase in the proportion of patients who received at least one UR medicine from 26% in 2001 
to 53% in 2011.33 There was at least one event per patient for UR or OL use in 79% of patients in 
2011 versus 58% in 2001.33 Fortunately, there was a decline in extemporaneous preparations from 
33% in 2001 to 10% in 2011.33 OL medicine use increased from 36% in 2011 from 42% in 2001. 
The most common reasons for OL medicine use in 2001 were the absence of paediatric information 
(38%) and route (34%), compared to 2011 when the main reasons were dose (17.3%) and age 
(9.9%).33 The positive effects of legislation are reflected in the decrease in extemporaneous 
compounding and a change in the most common reason for OL medicine use, namely the absence 
of paediatric information (2001) versus dose (2011).33 
The MCC is the statutory body in South Africa that regulates medicine registration and was 
established in terms of the Medicines and Related Substances Control Act 101 of 1965.2,47 
Registration of a medicine is possible if the necessary safety, quality and efficacy data from clinical 
trials for specified indications are available.2,47 In South Africa, Regulation 45(3) of the Medicines 
and Related Substances Control Act 101 of 1965 does not allow the distribution of information 
regarding OL medication, and Section 20(1)(b) prohibits the advertising of claims of therapeutic 
efficacy and effect other than those that the product registration satisfies. There is legislative control 
of medicine advertising according to the approved marketing license, which may place health care 
providers at an information disadvantage as information on OL medicine use may not be distributed 
by pharmaceutical or distribution companies.48 This also serves as protection for consumers and 
patients, especially limiting possible misleading information, expansion of indications, exaggeration 
of efficacy or de-emphasis of serious adverse events.1  
 
To generate information about the practice of UR or OL medicine use in highly specialised 
paediatrics in South Africa, we conducted a prospective descriptive survey at Tygerberg Hospital, 
a central/tertiary hospital in Parow, Cape Town, South Africa. 
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Chapter 2: Aim and methodology 
 
2.1 Aim and objectives  
2.1.1 Study aim 
The aim of the study was to prospectively document the UR and OL medicine use in children 
admitted to highly specialised paediatric wards at Tygerberg Hospital over a three-month period. 
 
2.1.2 Study objectives 
The primary objective of the study was to determine the frequency of UR and OL medicine events 
in highly specialised paediatrics. The secondary objective was to determine the most frequently 
prescribed UR and OL medicines per paediatric subspecialty. 
 
2.2 Research question and hypothesis 
The research question was what the extent and nature of UR and OL medicine use in highly 
specialised paediatrics (tertiary health care) at Tygerberg Hospital were. 
 
Hypothesis: UR and OL medicine use in highly specialised paediatrics at Tygerberg Hospital is a 
common practice. 
 
Null hypothesis: UR and OL medicine use in highly specialised paediatrics at Tygerberg Hospital is 
an uncommon practice. 
2.3 Study design and setting 
This was a prospective descriptive survey conducted over three consecutive months between 1 
November 2010 and 31 January 2011 in the highly specialised paediatric wards at Tygerberg 
Hospital, where there is a combination of general paediatric and highly specialised paediatric wards, 
as well as critical care wards for neonatology and paediatrics respectively. The highly specialised 
wards include beds for paediatric cardiology, endocrinology, gastroenterology, infectious diseases, 
nephrology, neurology, oncology, haematology, pulmonology, rheumatology and immunology. 
There are a total of 275 paediatric beds at Tygerberg Hospital, with 139 beds for highly specialised 
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paediatrics. This study was a substudy of a larger study documenting UR and OL medicine use in 
children admitted to Tygerberg Hospital. A prospective study design was suitable as the objective of 
the study was to determine exposure to an event (UR or OL medicine use) in the selected 
subjects/cohort admitted to highly specialised paediatric wards.  
 
2.4 Data collection and management 
The medicine charts of all children aged 0–16 years admitted to the highly specialised wards at 
Tygerberg Hospital during the study period were reviewed daily in the survey. The data was 
collected by the investigator only, after hours (between 4 and 7 pm) daily, over three consecutive 
months. Medical staff was informed about the study and the data collection but was not involved in 
the process of data collection. No identifiable data was collected, but each record received a unique 
study number that could be linked to the original patient record. Data was captured daily by the 
investigator in electronic format (Microsoft Excel) on a hand-held iPad. The following data was 
collected: demographic data (age, weight, sex and diagnosis) and data on medicines 
(pharmacological substances prescribed and administered to patients, excluding intravenous fluid, 
blood and blood products, and total parental nutrition) prescribed (medicine name, dose, frequency, 
formulation and route of administration). Information on total parental nutrition, intravenous fluid, 
blood and blood products prescribed was not collected. At the end of the patient’s admission period 
to the ward, completed data capture sheets were transferred to a study database on a central computer, 
analysed and imported into SSPS Version 19 for statistical analysis. 
 
2.5 Ethical considerations 
The study protocol was approved by the Health Research Ethics Committee, Faculty of Medicine 
and Health Sciences, at Stellenbosch University. A waiver of consent was granted by the Ethics 
Committee as no identifiable data was collected and the study posed minimal risk. The custodian of 
the hospital provided consent for access to patient files.  




2.6 Definition of the terms ‘unregistered’ and ‘off-label’ 
The Delphi survey proposed a definition of UR and OL medicine use for the purpose of research and 
regulation.6 However, the definition of UR and OL medicine use in published clinical studies 
documenting the extent of UR and OL medicine use is based on the definition by Turner,25 
Conroy5,35,38 and Ernest.27 Extemporaneous medicine use is the defining category for both 
definitions. In the Delphi survey, extemporaneous medicine use is defined as OL,6 while in the 
definition by Turner,26 Conroy5,35,38 and Ernest,27 extemporaneous use, if not added to the package 
insert, is defined as UR. During data analysis in this study, both definitions were used and reported 
in the results section.  
 
2.7 Data analysis  
The 2012 South African Medical Formulary50 manufacturer’s package insert and the January–
February 2013 edition of the MIMS desk reference51 were used as reference sources for data analysis. 
Each medicine event per patient was analysed and categorised as either (i) registered with the MCC 
and appropriately used; (ii) UR with the MCC; or (iii) OL medicine use as a medicine used outside 
the authorised product registration with the MCC. OL medicine use can be further divided into one 
of the following six categories: (i) OL for age; (ii) OL for dose; (iii) OL for route of administration; 
(iv) absence of paediatric information; (v) indication: a medicine used to treat an illness not covered 
by the MCC registration; and (vi) contraindication: a medicine utilised in the paediatric population 
despite documented contraindication for age group. 
  
Extemporaneous compounding and medicine manipulation (e.g. crushing of tablets or opening of 
capsules and suspending them in a liquid formulation) is a special category of medicine use and was 
analysed according to the definition by Conroy,5,35,38 Turner26 and Ernest27 (extemporaneous 
compounding is classified as UR) and then according to that of the Delphi survey6 (extemporaneous 
compounding is classified as OL). Extemporaneous compounding included any manipulation of a 
medicine at the time of administration or compounding of a registered medicine, resulting in a 
change in formulation, or manufacturing of a medicine from raw ingredients.27 Extemporaneous 
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manipulation was done by a pharmacist or by the nurse delegated to administer medication in the 
ward.  
 
A medicine event could be classified in more than one OL category. In classifying medicine events 
OL for dose, no deviation from the recommended calculated dose was allowed. There are no 
guidelines that standardise rounding up or down of a calculated dose.50 The extent of UR and OL 
medicine use was documented overall and per subspecialty.  
 
Medicines prescribed were categorised according to the WHO ATC classification to the fifth level.52 
This system classifies medicines into different groups according to the organ or system on which 
their chemical, pharmacological and therapeutic properties are exerted.52 The medicines are divided 
into 14 main groups (first level), with one pharmacological/therapeutic subgroup (second level).52 
The third and fourth levels comprise the chemical/pharmacological/therapeutic subgroups, and the 
fifth level is the chemical substance.52 Individual medicines were then classified to the fifth level 
using the WHO ATC classification, and this allowed evaluation of the reasons for OL and UR use 
of individual medicines.52  
 
The patients were classified into four age groups: newborns (0–27 days), infants (28 days to 23 
months), children (2–11 years) and adolescents (12–18 years) according to the International 
Conference on Harmonisation Guideline on Clinical Investigation of Medicinal Products in the 
Pediatric Population.53 
 
2.8 Statistical analysis  
Standard descriptive statistics were used. The frequencies of medicine events were calculated using 
the IBM Statistical Package for Social Sciences (SPSS software, version 19).  
 
2.9 Inclusion and exclusion criteria 
2.9.1 Inclusion criteria  
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All paediatric patients aged 0–18 years admitted to the highly specialised medical care wards 
(Level 3 care) at Tygerberg Hospital, which included neonates born outside of Tygerberg Hospital 
and referred for highly specialised paediatric health care at the hospital (Level 3 care).54 
 
2.9.2 Exclusion criteria  
 All neonates born in Tygerberg Hospital who were admitted to the neonatal critical care 
unit and neonatal wards. 
 All children admitted to the paediatric intensive care unit. 
 All children admitted for general paediatric health care (Level 2). 
 All children attending ambulatory clinics.  
 All children attending the paediatric emergency care department. 
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Chapter 3: Results 
3.1 Demographics 
There were 211 admissions, but nine patients received no medicines and two patients were excluded 
due to missing data. For the remaining 199 patients, the male-to-female ratio was 1:1.06 and the 
mean age was 50 months (range 1 month to 199.5 months; median age 33.6 months).  
 
3.2 Diagnosis 
The most common diagnosis was tuberculosis (TB) in 20% (40/199) of admissions, most frequently 
pulmonary TB (10.6%), followed by TB meningitis (7.5%), miliary TB (1%), congenital TB (1%) 
and tuberculous granulomas (0.5%) (Figure 3.1). Solid tumours accounted for 6% (12/199) of all 
admissions, with posterior fossa tumours the most frequent (2.5%), followed by neuroblastoma 
(1.5%), nephroblastoma (1.5%) and retinoblastoma (0.5%). Seizure disorders also accounted for 6% 
(12/199) of admissions, with generalised seizure disorders (5%) occurring more frequently than focal 
seizures (1%). Complicated gastroenteritis also accounted for 6% (12/199) of admissions. The 
majority of congenital cardiac defects 5.5% (11/199) were cyanotic cardiac lesions (4.5%). The 
remainder of the admissions were for bronchopneumonia (4%), airway obstruction (4%), 
neurodevelopmental disorders (4%), benign haematology (3.5%), disorders of the liver, gallbladder 
and biliary tree (4%), diabetes mellitus (3.5%), leukaemia (3.5%) and autoimmune disorders (3.5%). 
Chronic lung disease, glomerular disease and gastrointestinal disorders each represented 3% (Figure 












































Stellenbosch University  https://scholar.sun.ac.za
 
 17 
In the subcategory ‘other’, congenital malformations (genito-urinary and respiratory tract) accounted 
for 2% of admissions, while encephalopathies, diabetes insipidus and cardiac disease (syncope, 
palpitations and cardiac failure) each was responsible for 1.5% of admissions (Figure 3.2). Benign 
tumours, idiopathic intracranial hypertension, hydrocephalus, spontaneous bacterial peritonitis, 
foreign bodies, ambiguous genitalia, kidney disease (acute renal failure and chronic kidney disease) 
and infections (sepsis and nontuberculous meningitis) each accounted for 1% (2/199) of admissions. 
Ataxia, dermatophyte infections, pulmonary hypertension, hypoglycaemia and osteogenesis 
imperfecta each accounted for 0.5% (1/199) of admissions. 
ch.  
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3.3 Anatomical therapeutic chemical classification of medicines, defining extemporaneous use as 
unregistered use 
The 191 different medicines (n) prescribed in 1 507 medicine events were classified into medicine 
groups according to the WHO ATC classification (appendixes 1 and 2). The therapeutic subclasses 
(Figure 1) of medicines most frequently prescribed were general anti-infectives for systemic use 
(39% of medicine events with 49 medicines), medicines acting on the alimentary tact and 
metabolism (22% of medicine events with 33 medicines), medicines acting on the central nervous 
system (12% of medicine events with 19 medicines) and systemic hormonal preparations (5% of 
medicine events with 9 medicines). OL medicine events most prevalent in the subclasses were 
general anti-infectives for systemic use (15% of medicine events OL, 37 medicines OL), medicines 
acting on the alimentary tract and metabolism (4.1% of medicine events OL, 17 medicines OL) and 
medicines acting on the central nervous system (2.4% of medicine events OL, 12 medicines OL). 
UR medicine events were most frequent in the subclasses general anti-infectives for systemic use (J) 
(11% of medicine events UR, 12 medicines UR [4 medicines not registered, 9 medicines used 
extemporaneously]), followed by medicines acting on the alimentary tract and metabolism (A) (3.3% 
of medicine events UR, 11 medicines UR [3 medicines not registered, 8 medicines used 
extemporaneously]) and medicines acting on the cardiovascular system (C) (2.5% of medicine 
events UR, 9 medicines UR [6 medicines not registered, 4 medicines used extemporaneously]). 
 
In all the subclasses, dose was the most common reason for OL use (78% of OL medicine events) 
except for the systemic hormonal preparations, excluding sex hormones and insulin (H), for which 
indication (3% of OL medicine events) was the most common reason for OL use. In all the 
subclasses, extemporaneous medicine compounding was the most common reason for UR use (75% 
of UR use). In the subclass alimentary tract metabolism (A), mineral supplements (A12) and 
medicine for acid-related disorders (A02) were most frequently used OL for dose. The medicines 
most frequently used OL were zinc (32 OL events, 29 OL events for dose) and omeprazole (9 OL 
events, 6 OL events for dose). In the subclass of medicines acting on the central nervous system (N), 
psycholeptics (N05) followed by analgesics (N02) were most frequently used OL. Paracetamol was 
used OL most frequently (11 OL events, 10 OL events for dose), followed by diazepam (7 OL events, 
5 OL events for dose). For the subclass antineoplastic and immune-modulating agents (L), the 
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antineoplastic agent (L01) and cytrabine were most frequently used OL, and the reason for OL use 
was the lack of paediatric data (Appendix 1).
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Table 3.1: WHO ATC classification of medicine, defining extemporaneous use as UR use 
 
3.4 Overall medicine events 
A total of 1 507 medicine events were prescribed for 199 patients (Figure 3.3a). Each patient had an 
average of seven medicines prescribed per admission (range 1–28 medicines). Using the definition 
by Conroy and Turner of extemporaneous use as UR use,5,35,38 20% of these medicine events 
involved UR medicines for paediatric use in South Africa (Figure 3.3a). The majority of UR 
medicine events were due to extemporaneous compounding (15%), while medicines not registered 
with the MCC for children accounted for 5% of the medicine events. OL medicine use accounted 
for 29% of these medicine events, and the most common reasons for OL medicine use were OL use 
ATC classification No. of medicines 










Alimentary tract and metabolism 33 (22%) 17 62 (4.1%) 11 50 (3.3%) 
Blood and blood-forming organs 11 (4%) 2 17 (1.1%) 4 9 (0.6%) 
Cardiovascular system 11 (4%) 3 12 (0.8%) 9 37 (2.5%) 
Dermatologicals 12 (3%) 4 7 (0.5%) 0 0 
Genito-urinary system and sex 
hormones 
2 (0.1%) 1 1 (0.1%) 2 2 (0.1%) 
Systemic hormonal preparations (excl. 
sex hormones and insulin) 
9 (5%) 6 27 (1.8%) 2 2 (0.1%) 
General anti-infectives for systemic use 49 (39%) 37 226 (15%) 12 164 (11%) 
Antineoplastic and immune-modulating 
agents 
13 (4%) 5 10 (0.7%) 4 9 (0.6%) 
Musculoskeletal system 6 (2%) 3 9 (0.6%) 1 3 (0.2%) 
Central nervous system 19 (12%) 12 36 (2.4%) 6 19 (1.3%) 
Antiparasitic products 6 (0.9%) 4 6 (0.4%) 0 0 
Respiratory system 11(3%) 6 16 (1.1%) 1 1 (0.1%) 
Sensory organs 5 (1%) 2 3 (0.2%) 0 0 
Various 4 (1%) 0 0 2 4 (0.3%) 
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for dose (22%), followed by OL use for age (2%) and OL use for indication (1.5%). OL use for route, 
frequency and contraindication accounted for less than 1% of medicine events. 
 
Figure 3.3a: Summary of medicine events, defining extemporaneous use as a UR medicine event  
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If the definitions of the recent Dephi survey are applied, with UR use defined as OL use, only 5% of 
these medicine events involved UR medicines in South Africa for paediatric use, while OL medicine 
use increased to 40.5% of these medicine events (Figure 3.3b). The most important reasons for OL 
medicine use were OL use for dose (22%), followed by OL use for extemporaneous use (12%), OL 
use for age (2%) and OL use for indication (1.5%). OL use for route, frequency and contraindication 
accounted for less than 1% of medicine events.  
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3.5 Medicine events per subspecialty 
 
The number of patients per subspecialty ranged from 4 (rheumatology and immunology) to 44 
(neurology). Paediatric pulmonology and haematology-oncology had 38 and 31 patients 
respectively, followed by 24 for paediatric gastroenterology, 16 for paediatric infectious diseases, 
15 for paediatric endocrinology, 14 for paediatric cardiology and 13 for paediatric nephrology. The 
majority of medicine events occurred in the subspecialty paediatric gastroenterology with 360 
medicine events (24 patients) with a range of 1–28, followed by paediatric neurology with 266 
medicine events (44 patients) and haematology-oncology with 193 medicine events (31 patients), as 
well as infectious diseases with 193 medicine events (16 patients) (Table 3.2). Each patient in 
paediatric infectious diseases received a minimum of 4 medicines, with a range of 4–18 medicines. 
The average number of medicine events ranged from 3 to 13, with the highest average number of 
medicines per patient in the subspecialty paediatric infectious diseases (12 medicines per patient) 
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 Table 3.2: Patient numbers, medicine events, average medicines/patient and range of 
medicines/patient per subspecialty 
 
* Subspecialties with the highest average number of medicines per patient 
 
 
Extemporaneous medicine use was the categorical determinant between the two definitions as 
summarised in Table 3.3, which provides a comparison among the overall results per subspecialty 
when the different definitions are applied to the dataset. Overall, 15% of all medicine events took 

















Cardiology 14 63 5 1–9 
Endocrinology 15 92 6 1–19 
Gastroenterology 24 360 13* 1–28 
Infectious diseases 16 193 12* 4–18 
Nephrology 13 94 6 1–19 
Neurology 44 266 5 1–22 
Oncology and 
haematology 
31 192 6 1–21 
Pulmonology 38 232 6 1–19 
Rheumatology and 
immunology 
4 15 3 1–7 
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Table 3.3: Summary of overall results per subspecialty, defining extemporaneous use as (a) UR use 
or (b) OL use 
 
Subspecialty 
(a) Medicine events defining 
extemporaneous use as UR use 
(b) Medicine events defining 









Cardiology 25%* 6% 3% 32% 
Endocrinology 10% 3% 9%* 3% 
Gastroenterology 17% 39% 1% 51% 
Infectious diseases 30%* 42%* 6% 59%* 
Nephrology 22% 24% 15%* 29% 
Neurology 25%* 22%* 4% 39%* 
Oncology and 
haematology 
14% 27% 9% 32% 
Pulmonology 18% 27% 3% 41%* 
Rheumatology and 
immunology 
7% 40% 0% 47% 
* Subspecialties with the highest percentage of medicine events UR and OL 
 
UR medicine use was most frequent in infectious diseases (30%), followed by neurology and 
cardiology with a quarter (25%) of medicine events UR in each specialty (Figure 3.4a) if 
extemporaneous use is defined as UR.25,35 Just over one-fifth of medicine events were UR in 
nephrology (22%), 18% were UR in pulmonology, 17% were UR in gastroenterology and 14% were 
UR in oncology and haematology. In endocrinology, 10% of medicine events were UR, with only 
7% of medicine events UR in rheumatology and immunology. More than one-third of medicine 
events in infectious diseases (42%), rheumatology and immunology (40%) and gastroenterology 
(39%) were OL, followed by 27% for the subspecialties pulmonology and haematology-oncology 
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(Figure 3.4a). In nephrology, nearly a quarter of medicine events were OL (24%), with 22% of the 
medicine events OL for paediatric neurology, 6% OL for cardiology and 3% OL for endocrinology. 
 





Far lower UR medicine use was found when extemporaneous use was defined as OL use, with the 
most frequent UR use found in paediatric nephrology (15%), followed by paediatric oncology and 
haematology (9%) and paediatric endocrinology (9%). The incidence of paediatric infectious 
diseases UR events decreased to 6%, for paediatric neurology to 4% and for paediatric cardiology 
and paediatric pulmonology to 3% (Figure 3.4b). More than half the medicine events in paediatric 
infectious diseases (59%) and paediatric gastroenterology (51%) were OL, followed by paediatric 
rheumatology and immunology (47%), paediatric pulmonology (41%) and paediatric neurology 
(39%). In paediatric oncology and paediatric cardiology, 32% of the medicine events were OL in 
87%
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each of the respective specialties, with 29% OL in paediatric nephrology and 3% OL in paediatric 
endocrinology (Figure 3.4b). 
 






When extemporaneous use was defined as UR use, there were two categories of UR medicine use:  
medicines not registered with the MCC and extemporaneous medicine use. When this definition was 
applied, a quarter of medicine events in paediatric cardiology (25%), followed by decreasing 
frequency for the subspecialties paediatric infectious diseases (23%), paediatric neurology (21%), 
paediatric pulmonology (16%) and paediatric gastroenterology (14%), were UR for extemporaneous 
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(7%), paediatric oncology and haematology (6%), paediatric nephrology (5%) and paediatric 
endocrinology (1%) were UR for the category extemporaneous use (Figure 3.5). 
 
Medicine events for medicines not registered with the MCC for paediatric use were most frequent 
in paediatric nephrology (17%), paediatric endocrinology (9%), paediatric haematology and 
oncology (8%) and paediatric infectious diseases (7%) (Figure 3.5). Less than 5% of medicine events 
were UR for medicines not registered with the MCC in paediatric neurology (4%), paediatric 
gastroenterology (3%) and paediatric pulmonology (2%), with no medicine events UR in paediatric 



















Figure 3.5: Categorical distribution of UR medicine events per specialty, defining extemporaneous 
use as UR use 
 





3.6 Off-label medicine event reasons per subspecialty 
When OL medicine use was analysed, excluding extemporaneous use as OL use, the most 
common reason for OL medicine use in the majority of paediatric subspecialties was OL use for 
dose, followed by frequency and age (Table 3.4a). In paediatric cardiology, the most common 
reason for OL medicine use was a stated contraindication, accounting for 4.8% of medicine events. 
 
Table 3.4a: Subcategories of OL medicine use per subspecialty, excluding extemporaneous use as 
OL use 





































Categories of UR medicine use defining 
extemporaneous as UR
Extemporaneous Not registered
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Cardiology Contraindication (4.8%), indication (1.6%) 
Endocrinology Dose (1.1%), age (1.1%), route (1.18%) 
Gastroenterology Dose (30%), lack of data (3.3%), age (2.8%), route 
(1.7%), frequency (1.1%), indication (0.6%) 
Infectious diseases Dose (38.3%), age (2.1%), lack of paediatric data 
(1%), contraindication (0.5%) 
Nephrology Dose (21.3%), indication (3.2%) 
Neurology Dose (19.5%), indication (1.1%), age (0.4%), route 
(0.4%), frequency (0.4%)  
Oncology and haematology Dose (15%), indication (5.7%), lack of data (2.6%), 
age (1.6%), contraindication (1%), route (0.5%) 
Pulmonology Dose (19.4%), age (5.6%), frequency (0.9%), route 
(0.9%), indication (0.4%) 
Rheumatology and immunology Dose (0.3%), indication (0.1%)  
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When OL medicine use was analysed, including extemporaneous use as OL use, the most common 
reason for OL medicine use in the majority of paediatric subspecialties was OL use for dose (Table 
3.4b). Extemporaneous compounding was the most common reason for OL medicine use in 
paediatric cardiology (58%), paediatric neurology (53%) and paediatric infectious diseases (35%).  
 
Table 3.4b: Subcategories of OL medicine use per subspecialty, including extemporaneous use as 
OL use 
 
Subspecialty Reasons for OL use 
Cardiology Extemporaneous use (58%), contraindication (21%), dose 
(16%), indication (5%) 
Endocrinology Dose (28%), lack of data (28%), extemporaneous use (22%), 
indication (14%), route (8%) 
Gastroenterology Dose (51%), extemporaneous use (22%), lack of data (15%) 
Infectious diseases Extemporaneous use (35%), lack of data (12%), age (2%), 
frequency (1%) 
Nephrology Dose (64%), extemporaneous use (18%), indication (13.5%), 
lack of data (4.5%) 
Neurology Extemporaneous use (53%), dose (32%), lack of data (5%), 
frequency (4%), indication (3%), route (2%), age (1%) 
Oncology and haematology Dose (60%), indication (21%), extemporaneous use (9%), route 
(6%), lack of data (4%) 
Pulmonology Dose (45%), extemporaneous use (30%), frequency (10%), age 
(5.5%), lack of data (5.5%), indication (1%) 
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3.7 Medicines most frequently prescribed and reasons for off-label and unregistered use 
The 11 most commonly prescribed medicines were paracetamol (4.9%), isoniazid (4.6%), zinc 
(3.5%), prednisone (3.4%), pyrazinamide (2.4%), co-trimoxazole (2.2%), rifampicin (2%), 
ethambutol (1.9%), ethionamide (1.7%), amikacin (1.6%) and abacavir (1.5%) (Table 3.5.) More 
than half the medicine events for lamivudine (77%), zinc (62%) and amikacin (58%) were OL, as 
well as 42% for co-trimoxazole and 40% for isoniazid. When the most frequent medicines prescribed 
were analysed excluding extemporaneous use as OL use, the most frequent medicine for OL use was 
zinc (OL for dose 91%), three-quarters of the medicine events for lamivudine (77% for dose) were 
OL and more than half of the medicine events for amikacin (54% for dose) were OL. Almost an 
equal percentage of the medicine events for isoniazid (40%) and co-trimoxazole (39%) were OL for 
dose. Nearly one-third (27%) of the medicine events for prednisone were OL, and the reasons 
included indication (17%) and age (10%) (Table 3.5). 
 
When the most frequently prescribed medicines were analysed including extemporaneous use as OL 
use, nearly all the medicine events for the antimycobacterials were OL for extemporaneous use 
(pyrazinamide 95%, ethambutol 93% and ethionamide 92%). For zinc, 91% of medicine events were 
still OL for dose, and more than half the medicine events for the systemic anti-infectives (abacavir 
67% and amikacin 54%) and 39% for co-trimoxazole were OL for dose (Table 3.5). 
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Table 3.5: Summary of the 11 most frequently prescribed medicines and reasons for OL use, excluding (a) and including (b) extemporaneous 





(a) OL events excluding extemporaneous use (b) OL events including extemporaneous use  
 
OL medicine 
events n (%) 
Reason for OL use n (%) OL medicine 
events n (%) 
Reason for OL use n (%) 
Paracetamol 74 (4.9%) 11 (15%) Dose (15%) 11 (15%) Dose (15%) 
Isoniazid 53 (4.6%) 21 (40%) Dose (40%) 53 (4.6%) Extemporaneous (92%), dose (40%) 
Zinc 52 (3.5%) 32 (62%) Dose (91%), indication 6%, 
data (3%) 
32 (62%) Dose (91%), indication 6%, 
data (3%) 
Prednisone  52 (3.4%) 14 (27%) Indication (17%), dose (10%) 14 (27%) Indication (17%), dose (10%) 
 
Pyrazinamide 36 (2.4%) 7 (19.5%) Dose (14%), age (5.5%) 36 (2.4%) Extemporaneous (95%), dose (14%), age (5.5%) 
Co-trimoxazole  33 (2.2%) 14 (42%) Dose (39%), indication (3%) 14 (1 %) Dose (39%), indication (3%) 
Rifampicin 31 (2%) 2 (6.5%) Dose (3.3%), age (3.2%) 2 (6.5%) Dose (3.3%), age (3.2%) 
Ethambutol 29 (1.9%) 2 (7%) Dose (3.5%), age (3.5%) 29 (100%) Extemporaneous (93%), dose (3.5%), age (3.5%) 
Ethionamide 26 (1.7%) 2 (8%) Dose (4%), age (4%) 26 (100%) Extemporaneous (92%), dose (4%), age (4%) 
Lamivudine  26 (1.7%) 20 (77%) Dose (77%) 20 (77%) Dose (77%) 
Amikacin 24 (1.6%) 14 (58%) Dose (54%), indication (4%) 14 (58%)  Dose (54%), indication (4%) 
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3.8 Off-label medicine use in two or more categories  
A total of 69 patients in 31% of medicine events (n = 446) were exposed to OL medicine use in 2 or 
more categories. The most frequent combination was for extemporaneous use and dose in 26% (n = 
389) of medicine events in 56 patients. OL use for the combination of extemporaneous use, dose and 
age accounted for 11% of medicine events (n = 163) in 19 patients, while the combination of OL use 
for dose and age occurred in 8% of medicine events (n = 119) in 19 patients (Figure 3.6).  
 




Younger children were more likely to have an OL medicine event in two different categories, with 
the frequency of this decreasing with increasing age. The age group neonates had the largest number 
of OL medicine events for two different categories (3.5%), followed by infants (3%), children (2.7%) 
and adolescents (0.5%). In HIV-infected patients, 2.7% of medicine events (n = 292) were OL for 
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3.9 Unregistered medicine use  
UR medicine, including extemporaneous compounding, was the main reason for UR medicine use 
for antimycobacterials, used in the treatment of TB. The five most frequently used UR medicines 
were potassium chloride (100% UR), ethionamide (96% UR), ethambutol (96% UR), pyrazinamide 
(94% UR) and isoniazid (92% UR) (Table 3.6a). All were UR because of extemporaneous 
compounding. 
 




The most frequently used UR medicines, excluding extemporaneous use, were ofloxacin, ritonavir, 









Medicine  Medicine events 
n (%) 
UR medicine events  
n (%) 
Reason for UR use 
Potassium chloride 16 (1.1%) 16 (100%) Extemporaneous 
Ethionamide 25 (1.5%) 24 (96%) Extemporaneous 
Ethambutol 28 (1.9%) 27 (1.8%) Extemporaneous 
Pyrazinamide 36 (2.4%) 34 (96%) Extemporaneous 
Isoniazid 53 (3.5%) 49 (92%) Extemporaneous 
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3.10 Extemporaneously compounded medicines  
The extemporaneously compounded medicines manufactured at the Tygerberg Hospital pharmacy 
are manufactured based on pharmacopoeias, historical recipes and good pharmaceutical practice. 
The most frequently prescribed medicines used extemporaneously were essential 
antimycobacterials, as mentioned above, used in the treatment of TB. More than three-quarters 
(77%) of medicine events for isoniazid, pyrazinamide, ethambutol and ethionamide and 15% of 
medicine events for rifampicin were extemporaneous. Other extemporaneously compounded 
medicines included elemental supplements such as magnesium chloride, potassium chloride and 
potassium phosphate (62–100% UR), cardiac medicines such as spironolactone (100% UR) and the 
painkiller morphine (75% UR). 
 
Medicine Medicine events n 
(%) 
UR medicine 
events n (%) 
Reason for UR use 
Ofloxacin 15 (1%) 15 (100%) Not registered with the 
MCC 
Ritonavir 8 (0.5%) 8 (100%) Not registered with the 
MCC 
Amlodipine  7 (0.5%) 7 (100%) Not registered with the 
MCC 
Clonidine  7 (0.5%) 7 (100%) Not registered with the 
MCC 
Atenolol 5 (0.3%) 5 (100%) Not registered with the 
MCC 
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Table 3.7: Most frequently used extemporaneously compounded medicines
Extemporaneously compounded medicines 




% of medicine 
events UR  
Isoniazid 53 49 92% 









Spironalactone  16 16 100% 
Potassium chloride 16 16 100% 
Potassium phosphate 11 11 100% 
Morphine  8 6 75% 
Magnesium chloride 8 5 62% 
Rifampicin 31 5 16% 
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3.11 Medicine events per age categories 
Medicine events were analysed by age categories.53 The majority of medicine events (n = 1 507) 
were for infants (44%; n = 665), followed by children (42%; n = 640), adolescents (8%; n = 116) 
and neonates (6%; n = 86). UR medicine events, including extemporaneous use, were most frequent 
in children (23%), followed by neonates (22%), infants and toddlers (19%) and adolescents (8%) 
and decreased to 8% for children, 5% for neonates, 3% for infants and toddlers and 3% for 
adolescents if extemporaneous use was defined as OL. OL medicine events (including 
extemporaneous use) were equally frequent in neonates and infants (55% each), followed by children 
(40%) and adolescents (26%) (Figure 3.7).Younger paediatric patients were therefore more likely to 
be exposed to an OL medicine event as well as an OL or a UR medicine event, while appropriate 
medicine use was most frequent in adolescents and children (Figure 3.7). 
Figure 3.7: Medicine events per age categories, defining extemporaneous use as (a) UR use or (b) 
OL use 
 
Irrespective of whether OL medicine use included or excluded extemporaneous use, OL medicine 
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Categories of drug use 
Medicine events per age categories with extemporaneous use 
defined as (a) unregistered use or (b) off label use
Neonates Infants Children Adolescents
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medicine events in the age groups neonates (26.7%) and children (25.7%) and just over a fifth in the 
age group children (20.5%) were OL. When extemporaneous use was defined as OL use, it was the 
second most common reason for OL use in children (16.2% of medicine events) and infants (17.4% 
of medicine events OL for extemporaneous use) (Table 3.8). 
 




  Neonates Infants  Children  Adolescents 
Dose  26.7% 25.4% 20.5% 10.3% 
Extemporaneous 17.4% 16.2% 14.8% 6.0% 
Age  5.8% 2.6% 1.6% 0.0% 
Lack of paediatric data  1.2% 1.5% 1.1% 0.9% 
Route 1.2% 0.9% 0.5% 0.9% 
Frequency 1.2% 0.6% 0.2% 0.9% 
Indication 0.0% 0.8% 1.6% 6.0% 
Contraindication 1.2% 0.5% 0.2% 0.9% 
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3.12 Off-label and unregistered medicine events in HIV-infected patients  
Of the 199 patients, 24 were HIV infected, 167 were HIV negative and 8 were HIV exposed but 
uninfected. There were 292 medicine events in the 24 HIV-infected patients, which accounted for 
19.2% of the overall number of medicine events. These patients received 18% UR medicines (if 
extemporaneous use was included as UR) and 43% OL medicines. The most common reason for UR 
use was extemporaneous compounding (14%), followed by medicines not registered with the MCC 
(4%). The most common reasons were OL use for dose (35%), age (3%) and lack of paediatric data 
(2%). OL medicine use occurred in two different categories in 2.7% of these medicine events.  
 
Figure 3.8a: UR and OL medicine use in HIV-infected patients, defining extemporaneous use as 
UR use  
 
 
Of the 292 medicine events occurring in the HIV-infected patients, 4% were UR and 54% were OL 
(including extemporaneous use as OL use). The most common reasons were OL use for dose (35%), 
extemporaneous use (14%) and age (3%). OL use for lack of paediatric data accounted for 2% and 
route, indication and frequency accounted for 1% of medicine events each. OL medicine use 
HIV positive     
n = 292 
















Route 1% Indication 1%
Frequency 
1%
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occurred in two different categories in 2.7% of these medicine events. OL medicine use for more 
than two categories most frequently occurred for extemporaneous use (1.7%) and indication. 
 




The 24 HIV-infected patients were distributed over 5 specialties (paediatric infectious diseases – 10 
patients, paediatric gastroenterology – 9 patients, paediatric pulmonology – 3 patients and paediatric 
nephrology and neurology – 1 patient each). More than half the medicine events in HIV-positive 
children were in the age group infants (60%), followed by 32% in children and 8% in neonates. 
There were no HIV-postive adolescents (Figure 3.9). 
 
Figure 3.9: Age distribution of medicine events in HIV-positive children 
HIV infected 






























Nearly all the HIV-infected patients received highly active antiretroviral therapy (HAART) (23 
patients), except one patient in paediatric neurology for whom HAART had not yet been initiated. 







Table 3.9: Distribution of HIV-infected patients on HAART and TB treatment 
The most commonly prescribed medicines (Table 3.10) in HIV-positive patients were co-
trimoxazole (6.5%), lamivudine (5.8%), lopinavir/ritonavir (5.5%), abacavir (5.1%) and 










Subspecialty No. of HIV-infected patients on 
HAART 
No. of patients on TB 
treatment 
Infectious diseases 10 4 
Gastroenterology 9 5 
Pulmonology 3 2 
Nephrology 1 0 
Neurology 1 (not on HAART) 1 (TBM) 
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When the most frequent medicines prescribed were analysed, excluding extemporaneous use as OL 
use, medicine used OL for dose was the most common reason for OL medicine use. More than 80% 
of medicine events for each of the antiretrovirals used in the treatment of HIV were OL for dose 
(abacavir 86% OL, lamivudine 82% OL and lopinavir/ritonavir 80% OL), while 42% of the medicine 
events for co-trimoxazole were OL for dose. More than half the medicine events for zinc were OL 
(67%), with OL use for dose accounting for 50% of the OL events.  
 
Medicine Medicine 




(a) OL events excluding 
extemporaneous as OL 
(b) OL events including 




 n (%) 
Reason for OL 
use 
OL medicine 
events n (%) 




19 (6.5%) 8 (42%) Dose 8 (42%) Dose 
Lamivudine  17 (5.8%) 14 (82%) Dose 14 (82%) Dose 
Lopinavir/rit
onavir 
16 (5.5%) 13 (80%) Dose 13 (80%) Dose 
Abacavir 15 (5.1%) 13 (86%) Dose 13 (86%) Dose 
Multivitamin 13 (4.5%)     
Isoniazid 12 (4.1%)   12 (100%) Extemporaneous 
Zinc 12 (4.1%) 8 (67%) Dose (50%) 
Indication (17%) 
8 (67%) Dose 
Ritonavir 10 (3.4%)     
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Table 3.10: The 10 most commonly prescribed medicines in HIV-infected patients and reasons for 
OL use 
When medicine events in HIV-infected patients were analysed for their registration status, with 
extemporaneous use defined as UR use, the most common UR medicines prescribed in HIV-positive 
patients (Table 3.11) were isoniazid (4.1%), ritonavir (3.4%), ethambutol (2.7%), potassium chloride 
(1.4%) and pyrazinamide (1%). The reason for UR use was extemporaneous use in all the medicines, 
except ritonavir, which was not registered in South Africa.  
 
When the most frequent medicines prescribed in HIV-infected patients were analysed, with 
extemporaneous use defined as OL use, all the medicine events (100%) for the antimycobaterial 
isoniazid and 89% of the medicine events for ethambutol were OL for extemporaneous use. OL use 
for dose of the antiretrovirals ranged from 80% (lopinavir/ritvonvir) to 86% (abacavir). When 
extemporaneous used was defined as UR, more than 80% of the medicine events for the antivirals 
used to treat HIV infection (abacavir, lopinovir-ritonovir and lamivudine) and 42% of the medicine 
events for co-trimoxazole were OL for dose.  
Table 3.11: The five most frequently used UR medicines in HIV-infected patients and reasons 
for UR use  




(a) UR events including 
extemporaneous use 
(b) UR events excluding 
extemporaneous use 
UR medicine 
events n (%) 
Reason for UR 
use 
UR medicine 





12 (100%) Extemporaneous   
Ritonavir 10 
(3.4%) 
10 (100%) Not registered 10 (100%) Not registered 
with the 
MCC 
Ethambutol 9 (3.1%) 8 (89%) Extemporaneous   
Potassium 
chloride 
4 (1.4%) 4 (100%) Extemporaneous   
Pyrazinamide 12 
(4.1%) 
3 (25%) Extemporaneous   
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Chapter 4: Discussion of the results 
4.1 Discussion 
OL and UR medicine use in paediatrics is widespread globally, which was also demonstrated in this 
study with nearly half (49%) of medicine events being either OL or UR.7,8,9 UR medicine use in this 
study accounted for 20% of medicine events, with the majority of UR use due to extemporaneous 
compounding (15%), using the definition by Conroy et al and Turner et al, which is comparable to 
another study from Nigeria (20.4%) but higher than in Brazil (5.5%) and Palestine (7.1%) as other 
low- and middle-income countries.5,6,13,34,41 However, exposure to UR medicine events for the 
paediatric population in the current study was higher when compared to high-income countries such 
as Australia (2.6%), Germany (0.4%) and the Netherlands (14%).12,32,35 Extemporaneous medicine 
compounding was the most common reason for UR medicine events with a frequency of 10% in 
Finland, which is similar to this study with 15% extemporaneous use.30  
 
OL medicine use was high in India, a low-income country, with more than half of the medicine 
prescriptions (50.6%)27 being OL, while high-income countries reported OL medicine use ranging 
from 20% in the UK to 31%4 in the USA.27,26,4 The reported range of OL medicine use in middle-
income countries was 21.5–39.5%, which is comparable to the frequency of OL medicine use in this 
study (29%).13,41 The most common reason for OL medicine use was dose (29%), which is 
comparable to a study from Finland (22%) but higher than in the UK (8%) and lower than in Australia 
(47.4% ).4,26,32 Although dose was the most common reason for OL medicine use in both Germany 
and Finland, the second most common reason was lack of paediatric data, which differs from the 
current study in which OL use due to lack of paediatric data was particularly uncommon.4,12 OL 
medication use for age (2.1%) was also far lower than in studies from Brazil (7.9%), Finland (9.8%) 
and the UK (9.8%).13,4,26  
 
Overall, the medicines most frequently used in the majority of studies were anti-infectives for 
systemic use, respiratory medicines, medicines acting on the central nervous system and alimentary 
tract medicines.29,32 Only two studies utilised the WHO ATC classification methodology to classify 
medicines.29,32 Direct comparison could therefore be made with the studies that utilised the ATC 
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classification.29,32 In this study, the most frequent ATC categories prescribed were anti-infectives (J) 
for systemic use (39%), alimentary tract medicines (A) (22%) and medicines acting on the central 
(N) nervous system (12%). Similar ATC categories were used in Australia, but the frequency of use 
differed with medicines acting on the central nervous system most frequently used (39%), followed 
by alimentary tract medicines (15.4%) and anti-infectives (15.1%).32 The study from Malta found 
medicines acting on the respiratory system most frequently used (40%), followed by anti-infectives 
(23%) and central nervous system medicines (13%).29 The categories with the highest OL medicine 
events in the current study were anti-infectives (15% OL), alimentary tract medicines (4% OL) and 
central nervous system medicines (2.4% OL), while UR medicine events were most frequent for 
anti-infectives (11% UR), alimentary tract medicines (3.3% UR) and cardiovascular medicines 
(2.5% UR). The OL use differed from studies reported from Malta (59%) and Australia (39%), with 
both showing more frequent OL use of respiratory medicines,23,29 followed by central nervous 
system medicines (55% for Malta; 40.6% for Australia), anti-infectives (52% for Malta) and 
systemic hormonal preparations (36% for Australia).29,32  
 
There was, however, a higher average of seven medicines per patient in the current study (range 0–
28 medicine events/patient) than in other studies with an average of 2–4 medicines per patient.7,8,9 
The higher average and range of medicines per patient are probably due to the high prevalence of 
TB and HIV coinfection Southern Africa.55 HIV and TB are the leading infectious causes of death 
worldwide, with 80% of global HIV and TB infection occurring in Southern Africa.55,56 The Western 
Cape, the study region, is known to have a particularly high rate of TB, and the prevalence is 
estimated to be 944/100 000 adult population.55,57 The actual incidence of childhood TB is unknown, 
but the WHO estimates that there are 530 000 TB cases in children < 15 years (WHO national 
guidelines).57 In South Africa, 20% of TB cases are estimated to occur in children, with a prevalence 
of 511/100 000 in children < 5 years in the Western Cape.58 Worldwide, children account for 10% 
of new HIV infections.56 Continued transmission and a 4–5-fold rise in the incidence of TB with 
HIV coinfection have resulted in a dual epidemic.55 HIV coinfection alters the pathogenesis of TB, 
increasing the risk of developing active TB (from latent or new infections).56 More disturbing is the 
fact that South Africa also has a high burden of multimedicine-resistant and extremely medicine-
resistant TB. Dual therapy is often necessary with antimycobacterials and HAART.56,57 




The TB and HIV coinfection rate in this survey was 50%, which correlates with worldwide 
statistics.56 The participants who were HIV and TB coinfected formed a highly selected patient group 
in the study. In the subclass antimycobacterials (J04), extemporaneous compounding was the most 
common reason for UR use, and in the subclass antivirals for systemic use (J05), the most common 
reason for OL medicine use was dose, using the definition by Conroy and Turner.5,6 Extemporaneous 
compounding (14%) also accounted for the majority of UR medicine events (18%) in the HIV-
infected patients. The majority of the most commonly prescribed extemporaneously prepared 
medicines were therefore isoniazid, pyrazinamide, ethambutol, ethionamide and abacavir. For the 
medicine subclass of antimycobacterials (isoniazid, pyrazinamide, ethambutol and ethionamide), no 
information on extemporaneous medicine compounding is available in the South African package 
insert, the MIMS reference or the South African Medicines Formulary and therefore these medicines 
are UR.27,50,51  
 
The extent of extemporaneous compounding (67%) in the subclass antimycobacterials highlights the 
lack of child-friendly formulations. Clinical dosing of TB medicines takes place by weight-banded 
dosing charts, with recommended dosing ranges derived by the WHO.57 The weight-banded charts 
are derived from a medicine dosing range and supported by pharmacokinetic studies.57 Although the 
weight-banded dosing results in higher serum medicine levels for children aged less than two years, 
this is necessary to produce effective bactericidal activity.57 Systemic reviews have reinforced the 
safety profile of weight-banded dosing by providing evidence of no risk of increased toxicity, 
especially hepatotoxicity due to pyrazinamide or isoniazid use or optic neuritis due to ethambutol 
use.57 Weight-banded dosing charts are used as a standard of clinical care in treatment of childhood 
TB and provide dosing guidance to clinicians with respect to tablets that are scored and manipulation 
of antimycobacterials tablets so that the therapeutic needs of paediatric patients are met.  
 
Pharmaceutical justification for extemporaneous compounding is the absence of an equivalent 
registered medicine formulation,5,25,27,35,38 making extemporaneous compounding justifiable in 
certain situations. With respect to orphan and rare diseases, registered formulations or viable 
alternatives may not meet the special therapeutic needs of treatment.27 It may also not be profitable 
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for pharmaceutical companies to manufacture and distribute a medicine.59 The available 
formulations and strengths of a medicine may be limited, and in the presence of allergies to specific 
ingredients in a medicine, extemporaneous compounding may be necessary, as demonstrated for the 
anti-TB medicines in this study.27 The risks associated with extemporaneous medicine use are 
formulation failure due to medicine degradation, excipients and medicine binding, and the use of 
inadequately validated and historical formulas.27 Microbial contamination during manufacturing or 
growth and by-products of microbial degradation in the particular medicine can lead to spoilage.27 
This is also a risk factor for infection, especially for immunocompromised patients.27 Calculation 
errors can occur during manufacturing and medicine administration.27 Ingredients and excipients 
should be physiologically age appropriate and religiously acceptable and should not precipitate 
systemic or local adverse reactions. Health, safety and quality assurance should be maintained during 
manufacturing, storing and administering the medicine.27,59 
 
The majority of medicine events for antiretroviral medicines were OL for dose when compared to 
the South African manufacturers package insert and the South African Medicines Formulary but 
correlated well when compared to the standardised weight-banded dosing charts used in clinical 
practice.60 The clinical dosing of HAART is guided by weight-banded paediatric dosing charts 
compiled by the Child and Adolescent Committee of the HIV Clinicians Society in collaboration 
with the National Department of Health.60 Weight-banded dosing charts were developed by the 
WHO paediatric ARV working group using scientific data and pharmacokinetic models.61 There are 
target doses for ARVs that are targeted within the specific weight band.61 The optimal dose within a 
weight band was based upon manufacturers’ information, ARV formulation choices, clinical studies 
and expert paediatric pharmacology consultation.61 Dosing within a particular weight band may be 
above or below that recommended by the manufacturer.61 Derived doses on the weight bands avoid 
dosing a medicine below 90% or above 125% of the target dose.61 For the antiretroviral medicines, 
68% of the medicine events were OL for dose when compared to the reference sources but correlated 
with the weight-banded dosing charts used in clinical practice. Weight-banded dosing charts for HIV 
and TB therapy are scientifically derived and clinically useful; clinicians should seek the MCC’s 
approval to add these weight-banded charts to package inserts and pharmacological resources. 
Ritonavir was the only ARV not registered in South Africa, although pharmacokinetic data is 
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available for infants and children, especially used to boost other protease inhibitors in combination 
with TB therapy.61 Stavudine was the only antiretroviral medicine used in an extemporaneous 
manner.61  
 
Individual medicines worth mentioning are paracetamol and captopril. Paracetamol was listed as the 
most frequently used medicine in seven studies with a medicine event frequency ranging from 5% to 
18.3% and with OL medicine events for the medicine ranging from 4% to 52%.4,13,26,35,41 
Paracetamol was prescribed in 4.7% of medicine events in this study, with an OL medicine event 
rate of 15%, which was similar to findings from a study in Nigeria.41 With 15% of the medicine 
events being extemporaneous, all the medicine events for the antihypertensive captopril were not 
registered, with Croatia, Brazil, Germany and Palestine also reporting similarly.10,12,13,34  
 
For the subspecialties paediatric neurology and paediatric endocrinology, all the OL and UR 
medicine events were higher, while in paediatric endocrinology, UR medicine events were higher 
and OL events lower when compared to a similar study in Croatia.10 The frequency of OL medicine 
events in the subspecialty paediatric pulmonology was 27%, which is comparable to the results 
reported by Schmiedl et al, with 29.8% of medicine events being OL, but lower than in Malaysia 
(35.6%).62 The most common reason for OL use was dose, which differed from Malaysia and 
Germany where it was indication. The subclass of medicine used most frequently OL was to treat 
obstructive airway disease, which was comparable to Germany and Malaysia.62,63  
 
 In paediatric oncology with 27% OL use, with the most common reason being dose (15%), the 
finding was similar to the findings reported by Conroy et al (26%) and Van Den Berg et al (21%).49,64 
UR medicine use was similar to that found by the studies by Conroy et al (19%) and Paveveski 
(18%).49,55,10 The most common reason was dose, similar to a report by Van den Berg et al.64 The 
reason for UR medicine use for antineoplastic medicines was medicines not registered with the MCC 
(17%), while Conroy reported the UR reason as extemporaneous use (16%).49  
 
OL medicine use in paediatric gastroenterology in this survey at 39% was similar to that in paediatric 
gastroenterology units in the UK (37%) but higher in comparison to a similar study in Croatia 
(10.8%).10,65 UR medicine events (17%) in paediatric gastroenterology were higher when compared 
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to reports from the UK (12%) and Croatia (2.7%).10,65 A possible reason for the higher rates may be 
the increased frequency of extemporaneous use of medicines in this study population (14%).  
 
In paediatric cardiology, 6% of medicine events were OL and 25% were UR. OL medicine events 
were lower and UR medicine events were higher in this survey compared to that by Bajcetic et al66 
in which 47% of medicine events were OL and 11% were UR. The most common reason for OL use 
in this study was contraindication, followed by dose and lastly unspecified indication, which differed 
from the results of Bajcetic et al66 with the most common reasons for OL use being dose and age.66 
Extemporaneous compounding of spironolactone was common in both studies but occurred at a 
higher frequency in this study (100%) compared to the study by Bajcetic et al (43%).66 
 
4.2 Limitations of the study 
The study was conducted in a tertiary health care setting (highly specialised paediatrics) where 
children with complex pathology were admitted. The results may therefore not be generalisable to 
the general paediatric population as the severity of disease may differ from children managed in 
secondary level health care facilities or in ambulatory paediatric clinics, therefore rendering the 
medicines utilised highly context specific. The medicine events in the age group neonates (0–27 
days) may be underrepresented as these children are mostly admitted to neonatal wards, which were 
not included in this study. The results may therefore not be generalisable to the neonatal population. 
Medicine manipulation at the point of care/administration is possibly underrepresented since we did 
not directly observe dispensing/manipulation practices at the point of medicine administration by the 
dispensing nurse. We only recorded medicines that were known to be extemporaneously 
compounded in the hospital pharmacy. There are also no clinical guidelines to guide manipulation 
at the point of medicine administration, which are important to develop. Extemporaneous 
manipulation is done at the dispensing health staff’s discretion and is highly dependent on the clinical 
context in which medicine is being utilised; this further makes the generalisability of these results 
difficult. The odds of an adverse medicine reaction in relation to OL or UR medicine utilisation or 
the number of medicines prescribed cannot be commented on as this was not part of the aims and 
objectives of the study. The study duration of three consecutive months may not have been sufficient 
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for data collection in a highly selected population with complex and sometimes rare and orphan 
diseases that require subspecialist care.  
 
4.3 Conclusions and recommendations  
OL medicine use (29%) and UR medicine use (20%) were common in highly specialised paediatric 
inpatient care at Tygerberg Hospital in Cape Town. The most common reasons for OL use were dose 
(22%) and age (2.1%), while extemporaneous compounding (15%) was the most common reason 
for UR medicine use. In the subspecialties paediatric infectious diseases and gastroenterology, nearly 
half the medicine events were OL, while the highest frequency of UR medicine events was 
documented in paediatric infectious diseases (30%), cardiology and neurology (25% each). 
Extemporaneous and OL medicine preparations for infectious diseases (23%) are a cause for concern 
since the burden of paediatric disease involves mostly infections such as TB and HIV and highlights 
the lack of suitable paediatric-friendly medicine formulations.   
 
The results of the survey provide evidence for UR and OL medicine use in highly specialised 
paediatric care. In the future, studies should be conducted to document the odds of an adverse 
medicine event in relation to UR and OL medicine use. Legislative changes as in the USA and 
Europe that compel the pharmaceutical industry to generate paediatric-specific safety and efficacy 
data by its inclusion in clinical trails are vitally important and recommended for the South African 
context.  




1. Rago L, Santoso B. Drug regulation: history, present and future. In: Van Boxtel CJ, Santoso 
B, Edwards IR, eds. Drug benefits and risks: international textbook of clinical pharmacology. 
2nd edition. Uppsala, Sweden: Uppsala Monitoring Centre; 2008.   
2. SANCTR. The Medicines Control Council. Available from 
http://www.sanctr.gov.za/YourRights/TheMedicinesControlCouncil/tabid/176/default.aspx 
(Accessed 24/08/2015).   
3. Kemper EM, Merkus M, Wierenga PC, Van Rijn PC, Van der Werff D, Lie-A-Huen L, et al. 
Towards evidence-based pharmacotherapy in children. Pediatric Anesthesia 2010 Dec 
28;21(3):183–9.   
4. Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H. 
Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland: 
the status before and after the European Union Paediatric Regulation. Journal of Clinical 
Pharmacy and Therapeutics 2013 Dec 16;39(2):144–53.   
5. Conroy S. Unlicensed and off-label drug use. Pediatric Drugs 2002;4(6):353–9.   
6. Neubert A, Wong I, Bonifazi A, Catapano M, Felisi M, Baiard P, et al. Defining off-label and 
unlicensed use of medicines for children: results of a Delphi survey. Pharmacological Research 
2008 Nov;58(5-6):316–22.   
7. Pandolfini C, Bonati M. A literature review on off-label drug use in children. European Journal 
of Pediatrics 2005 May 24;164(9):552–8.   
8. Magalhães J, Rodrigues AT, Roque F, Figueiras A, Falcão A, Herdeiro MT. Use of off-label 
and unlicensed drugs in hospitalised paediatric patients: a systematic review. European Journal 
of Clinical Pharmacology 2014 Oct 16;71(1):1–13.   
9. Ivanovska V, Rademaker CMA, Van Dijk L, Mantel-Teeuwisse AK. Pediatric drug 
formulations: a review of challenges and progress. Pediatrics 2014 Jul 14;134(2):361–72.   
10. Palčevski G, Skočibušić N, Vlahović-Palčevski V. Unlicensed and off-label drug use in 
hospitalized children in Croatia: a cross-sectional survey. European Journal of Clinical 
Pharmacology 2012 Feb 4;68(7):1073–7.   
Stellenbosch University  https://scholar.sun.ac.za
 
 53 
11. Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off-label and 
unlicensed medicines in children: a prospective cohort study of unplanned admissions to a 
paediatric hospital. British Journal of Clinical Pharmacology 2014 Feb 21;77(3):545–53.   
12. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of 
unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Safety 
2004;27(13):1059–67.   
13. Santos DB, Clavenna A, Bonati M, Coelho HLL. Off-label and unlicensed drug utilization in 
hospitalized children in Fortaleza, Brazil. European Journal of Clinical Pharmacology 2008 
Aug 7;64(11):1111–8.   
14. Schirm E, Tobi H, Van Puijenbroek EP, Monster-Simons MH, De Jong-Van den Berg LTW. 
Reported adverse drug reactions and their determinants in Dutch children outside the hospital. 
Pharmacoepidemiology and Drug Safety 2004 Mar;13(3):159–65.  
15. Conroy S. Association between licence status and medication errors. Archives of Disease in 
Childhood 2010 Dec 3;96(3):305–6.   
16. Pfister DG. Off-label use of oncology drugs: the need for more data and then some. Journal of 
Clinical Oncology 2012 Jan 17;30(6):584–6. 
17. De Decker R, Gordon-Graham E, Seller N, Lawrenson J. Surprises of off-label drug use – 
where had all the prostin gone? South African Medical Journal 2009;99(6). 
18. Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of 
rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014 Jun 
11;83(2):142–50. 
19. Hill P. Off-license and off-label prescribing in children: litigation fears for physicians. 
Archives of Disease in Childhood 2005 Feb 1;90(suppl 1):i17–8.   
20. Lenk C, Koch P, Zappel H, Wiesemann C. Off-label, off-limits? Parental awareness and 
attitudes towards off-label use in paediatrics. European Journal of Pediatrics 2009 Mar 
11;168(12):1473–8.   
21. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert 
Opinion on Drug Safety 2004;3(2):81–3.   
22. Sinha Y, Cranswick NE. How to use medicines in children: principles of paediatric clinical 
pharmacology. Journal of Paediatrics and Child Health 2007 Mar;43(3):107–11.   
Stellenbosch University  https://scholar.sun.ac.za
 
 54 
23. Thalidomide Victims Association of Canada. The Canadian tragedy. Available from 
http://www.thalidomide.ca/the-canadian-tragedy/ (Accessed 20/07/2015).  
24. Casavant MJ, Griffith JRK. Pediatric pharmacotherapy Part 1: The history of pediatric drug 
therapy: learning from errors, not trials. Available from 
http://www.medscape.com/viewarticle/726236_1 (25/07/2015).  
25. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clinical Pharmacology & 
Therapeutics 2012 Apr 4;91(5):796–801.   
26. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off-label drug use in paediatric 
wards: prospective study. BMJ 1998 Jan 31;316(7128):343–5.   
27. Ernest TB, Craig J, Nunn A, Salunke S, Tuleu C, Breitkreutz J, et al. Preparation of 
medicines for children – a hierarchy of classification. International Journal of 
Pharmaceutics 2012 Oct;435(2):124–130. 
28. The NHS Pharmaceutical Quality Assurance Committee, Mark Jackson Andrew Lowey 
staff. Handbook of extemporaneous preparation: a guide to pharmaceutical compounding. 
London: Pharmaceutical Press; 2010. 
29. Ellul IC, Grech V. Off-label and unlicensed paediatric prescribing in a community setting: a 
prospective longitudinal cohort study in Malta. Paediatrics and International Child Health 
2014 Feb;34(1):12–8.   
30. Jain SS, Bavdekar SB, Gogtay NJ, Sadawarte PA. Off-label drug use in children. The Indian 
Journal of Pediatrics 2008 Sep 22;75(11):1133–6.   
31. Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C, et al. Off-label drug use in 
hospitalized children. Archives of Pediatrics & Adolescent Medicine 2007 Mar 1;161(3):282.   
32. Czarniak P, Bint L, Favié L, Parsons R, Hughes J, Sunderland B. Clinical setting influences 
off-label and unlicensed prescribing in a paediatric teaching hospital. PLOS ONE 2015 Mar 
10;10(3):e0120630.   
33. Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H. 
Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland: 
the status before and after the European Union Paediatric Regulation. Journal of Clinical 
Pharmacy and Therapeutics 2013 Dec 16;39(2):144–53.   
Stellenbosch University  https://scholar.sun.ac.za
 
 55 
34. Khdour MR, Hallak HO, Alayasa KSA, AlShahed QN, Hawwa AF, McElnay JC. Extent and 
nature of unlicensed and off-label medicine use in hospitalised children in Palestine. 
International Journal of Clinical Pharmacy 2011 May 13;33(4):650–5.   
35. Conroy S. Survey of unlicensed and off-label drug use in paediatric wards in European 
countries. BMJ 2000 Jan 8;320(7227):79–82.   
36. Oguz SS, Kanmaz HG, Dilmen U. Off-label and unlicensed drug use in neonatal intensive care 
units in Turkey: the old-inn study. International Journal of Clinical Pharmacy 2012 Jan 
11;34(1):136–41.   
37. Lee JL, Md Redzuan A, Mohamed Shah N. Unlicensed and off-label use of medicines in 
children admitted to the intensive care units of a hospital in Malaysia. International Journal of 
Clinical Pharmacy 2013 Sep 11;35(6):1025–9.   
38. Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Seminars 
in Fetal and Neonatal Medicine 2005 Apr;10(2):115–22.   
39. Conroy S, Peden V. Unlicensed and off-label analgesic use in paediatric pain management. 
Pediatric Anesthesia 2001 Jul 26;11(4):431–6.   
40. Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, et al. Omalizumab in 
Children. Pediatric Drugs 2014 Nov 18;16(6):491–502.   
41. Okechukwu RC, Aghomo OE. Prescription pattern of unlicensed and off-label medicines for 
children aged 0-5 years in a tertiary hospital and a primary health care centre in Nigeria. SAJBL 
2009 Dec;2(2):62–6.  
42. Raiman S, Knight SE, Eley B, Welzel TB. Use of polyclonal intravenous immunoglobulin at 
a paediatric referral hospital in South Africa between 2009 and 2012. Journal of Clinical 
Immunology 2015 Sep 14; 
43. Dos Santos DB, Coelho HLL. Adverse drug reactions in hospitalized children in Fortaleza, 
Brazil. Pharmacoepidemiology and Drug Safety 2005 Nov 15;15(9):635–40.   
44. Mukattash T, Hawwa AF, Trew K, McElnay JC. Healthcare professional experiences and 
attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials. European 
Journal of Clinical Pharmacology 2011 Jan 18;67(5):449–61.   
Stellenbosch University  https://scholar.sun.ac.za
 
 56 
45. Haslund-Krog S, Mathiasen R, Christensen HR, Holst H. The impact of legislation on drug 
substances used off-label in paediatric wards – a nationwide study. European Journal of 
Clinical Pharmacology 2014 Jan 8;70(4):445–52.  
46. Rocchi F, Paolucci P, Ceci A, Rossi P. The European paediatric legislation: benefits and 
perspectives. Italian Journal of Pediatrics 2010 Aug 17;36(1):56. 
47. Pfizer. The Medicine Control Council and its function. Available from 
http://www.pfizer.co.za/wellatpfizer/about-clinical-trials/the-medicine-control-council-and-
its-function/2136.aspx (Accessed 20/07/2015). 
48. Jansen R-M. The off-label use of medication in South Africa – what about some information 
for medical practitioners? S Afr Med J 2009;99(6):438–9.  
49. Conroy S. Unlicensed and off-label drug use in acute lymphoblastic leukaemia and other 
malignancies in children. Annals of Oncology 2003 Jan 1;14(1):42–7.   
50. Pharmacology D of C, Sciences F of H, Blockman M, Barnes KI. South African medicines 
formulary. 9th edition. Rondebosch, South Africa: Health & Medical Publishing Group; 2010.   
51. Mims desk reference 2012/2013. Volume 50. Johannesburg: MIMS; 2013.  
52. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC 
classification and DDD assignment 2013. Oslo: WHO; 2012. 
53. ICH. Harmonised tripartite guideline: clinical investigation of medicinal products in the 
pediatric population E11 (dated 20 July 2000). Available from 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/Ste
p4/E11_Guideline.pdf (Accessed 22/12/2015). 
54. The future of health care in the Western Cape: a draft framework for dialogue. Cape Town: 
Western Cape Government; 2011. 
55. Ayles HM, Sismanidis C, Beyers N, Hayes RJ, Godfrey-Faussett P. ZAMSTAR, the 
Zambia South Africa TB and HIV reduction study: design of a 2 × 2 factorial community 
randomized trial. Trials 2008 Nov 7;9(1):63. 
56. Venturini E, Turkova A, Chiappini E, Galli L, De Martino M, Thorne C. Tuberculosis and 
HIV co-infection in children. BMC Infectious Diseases 2014 Jan 8;14(1):S5.  
57. WHO, Stop TB Partnership. Guidance for national tuberculosis programmes on the 
management of tuberculosis in children. Switzerland: WHO; 2014. 
Stellenbosch University  https://scholar.sun.ac.za
 
 57 
58. Zar HJ, Eley B, Nicol MP, Figaji A, Hawkridge A. Advances in childhood tuberculosis – 
contributions from the University of Cape Town. South African Medical Journal 2012 
Jun;102(6):518–521. 
59. Spark MJ. Compounding of medicines by pharmacies: an update. Maturitas 2014 
Aug;78(4):239–240. 
60. Available from 
http://www.sahivsoc.org/upload/documents/HIV%20guidelines%20_Jan%202015.pdf 
(Accessed 15/10/2015).  
61. WHO, UNICEF. Antiretroviral therapy for HIV infection in infants and children: towards 
universal access. Annex E: prescribing information and weight-based dosing of available 
ARV formulations for infants and children. Geneva: WHO; 2011. 
62. Schmiedl S, Fischer R, Ibáñez L, Fortuny J, Klungel OH, Reynolds R, et al. Utilisation and 
off-label prescriptions of respiratory drugs in children. PLOS ONE 2014 Sep 2;9(9):e105110.   
63. Mohamad NF, Mhd Ali A, Mohamed Shah N. Respiratory drugs prescribed off-label among 
children in the outpatient clinics of a hospital in Malaysia. International Journal of Clinical 
Pharmacy 2014 Dec 9;37(1):127–32.   
64. Van den Berg H, Tak N. Licensing and labelling of drugs in a paediatric oncology ward. British 
Journal of Clinical Pharmacology 2011 Aug 8;72(3):474–81.   
65. Dick A, Keady S, Mohamed F, Brayley S, Thomson M, Lloyd BW, et al. Use of unlicensed 
and off-label medications in paediatric gastroenterology with a review of the commonly used 
formularies in the UK. Alimentary Pharmacology and Therapeutics 2003 Feb;17(4):571–5.   
Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, et al. Off-label and unlicensed drugs use 
in paediatric cardiology. European Journal of Clinical Pharmacology 2005 Sep 8;61(10):775–9.  






Appendix 1. Anatomical Therapeutic Classification (ATC) of Medicines as defined by Conroy(5,15,35,38,39,49), Turner(26) and Ernest(27)  
 
 
Therapeutic Class WHO ATC Active substance  







events  Criterion for OL/UR use  
A. Alimentary tract and metabolism  
A01  Stomatological preparations            
Antiinfectives and antiseptics for local and systemic 
treatment  A01AB09 Clotrimazole  2 1 1 Extemporaneous (1) route (1) 
Corticosteroids for local oral treatment  A01AC01 Triamcinolone  1       
Other agents for oral treatment  A01AD02 Benzydamine 1       
A02  
Medicines for acid related 
disorders            
H2 receptor antagonists  A02BA02 Ranitidine  1       
Proton pump inhibitors  A02BC01 Omperazole 14 7 9 
Extemporaneous (7) Dose (6) 
frequency (2) age (1) 
Other medicines for eptic ulcer and gastro-oesophageal 
reflux disease A02BX02 Sucralfate 1 1   Not registered (1) 
A03 
Medicines for functional 
gastrointestinal disorders           
Propusives  A03FA01 Metoclopramide 3   1 Age (1) 
  A03FA03 Domperidone  1       
A04 
Anit-emetics and anti-
nauseants           
Sertaonin antagonists  A04AA01 Ondansetron 4   1 Dose (1) 
A06 Medicines for constipation           
Osmotically acting laxatives A06AD11 Lactulose 8   3 Dose (2) age (1)  
  A06AD17 Sodium Phosphate  1   1 Lack of paediatric data (1) 
Enemas  A06AG04 Glycerol 2   1 Lack of paediatric data (1) 
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agents            
Antibiotics  A07AA02 Nystatin  4       
A09 Digestives, include. Emzymes           
Emzyme preparations  A09AA02 Pancreatin  1 1   Extemporaneous (1)  
A10 Medicines used in diabetes            
Insulins and analogues for injection, fast acting  A10AB01 Insulin  30       
Insulins and analogues for injection, ultra fast acting  A10AB05 Insulin 3       
Insulins and analogues for injection, intermediat acting  A10AC01 Insulin  32       
A11 Vitamins           
Multivitamins and other minerals, incl combinations  A11AA03 Multivitamin Syrup 80   1 Dose (1) 
Vitamin A Plain A11CA01 Retinol 4   1 Dose (1) 
Vitamin D analogues A11CC01 Ergocalciferol 15       
  A11CC03 Alphacalidiol 3       
  A11CC04 Calcitriol 1 1 1 Not registered (1) dose (1) 
Vitamin B1, Plain A11DA01 Thiamine  2   2 Dose (2)  
Vitamin B complex, plain A11EA Vitamin B complex 1       
Other plain vitmain preparations  A11HA02 Pyridoxine  14 2 1 Extemporaneous (2) dose (1) 
  A11HA03 Vitamin E 3   1 Dose (1) 
  A11HA05 Biotin 1 1   Extemporaneous (1) 
A12 Mineral Supplements           
Calcium A12AA01 Phosphate 11 11   Extemporaneous (11)  
  A12AA04 Calcium carbonate 10   1 Dose (1) 
Potassium A12BA01 Potassium chloride 16 16 2 
Extemporaneous (16) dose (1) 
age (1) 
Zinc A12CB02 Zinc gluconate  53   32 
Dose (29) indication (2) Lack of 
data (1) 
Magnesium A12CC01 Magnesium chloride 8 8 3 
Extemporaneous (8) lack of 
data (2) age(1) 
  A12CC02 Magnesium suphate  2 1   Not registered (1) 
      333 50 62   
B. Blood and blood forming organs  
B01 Anti-thrombotics           
Heparin group B01AB05 Enoxaparin sodium  1 1   Not registered (1) 
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Platelet aggregaion inhibitors excl. heparin B01AC06 Asprin 1       
B02 Anti-haemorrhagics           
Antifibrinolytics B02AA02 Tranexamic acid 3       
Vitamin K  B02BA01 Phytomenadione  8       
Blood coagulation factors  B02BD02 Factor 8 1       
B03 Anti-anemic preparations            
Iron bivalet, oral preparations  B03AA03 Ferrous lactate/salts  12 1 2 Extemporaneous (1) dose (2)  
Folic acid and derivates  B03BB01 Folic Acid 20 3 15  Extemporaneous (3) dose (15) 
Other anti-anemic preparations  B03XA02 Epoetin  1       
B05 
Blood substitutes and 
perfusion solutions            
Blood substitutes and plasma protein fractions  B05AA01 Albumin 20% 1       
Salt solutions  B05CB04 Sodium bicarbonate  4 4   
Not registered (2) 
Extemporaneous (2) 
  B05XA03 Sodium chloride 5% 3       
      55 9 17   
C. Cardiovascular System  
C02 Antihypertensives            
Alph-adrenoreceptor antagonists  C02CA04 Doxazosin 1 1   Not registered (1) 
C03 Diuretics            
Low ceiling diuretics, thiazides plain C03AA03 Hydrochlorothiazide 1 1   Extemporaneous  (1) 
Highceiling diuretics, sulponamides plain C03CA01 Furosemide 22 1 4 Extemporaneous (1) Dose (4)  
Aldosterone antagonists  C03DA01 Spironolactone  16 16 
 
Extemporaneous (16) 
C07 Beta blocking agents            
Beta blocing agents, non selective  C07AA05 Propanolol 2       
Beta blocking agents,selective  C07AB03 Atenolol 5 5   Not registered (5) 
C08 Calcium channel blockers           
Dihydropyridine derivatives  C08CA01 Amlodipine  7 7   Not registered (7) 
  C08CA05 Nifedipine  1 1   Not registered (1) 
C09 
Agents acting on the rennin-
angiotensin system            
ACE inhibitors, plain C09AA01 Captopril 2 2   
Not registered (1) 
extemporaneous (1) 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 
 61 
  C09AA02 Enalapril 3 3 1 Not registered (3) indication(1)  
C10 Lipid modifying agents            
Bile sequatrants  A10AC01 Cholestyramine  7   7 Dose (7)  
      67 37 12   
D. Dermatologicals 
D01 
Anti-fungals for dermatological 
use           
Antibiotics D01AA01 Nystatin 16   1 Lack of paediatric data (1) 
Antifungals for sytemic use D01BA01 Griesofulvin 2       
D02 Emmolients and protectives           
Zinc poducts  D02AB Zinc castor oil ointment  5   4 Lack of paediatric data (4) 
Soft paraffin and fat products  D02AC Aqueous cream  4       
    Haldens emulsifying base 3       




dermatological use            
Anti-virals D06BB03 Aciclovir 1   1 Lack of paediatric data (1) 
D07 
Corticosteroid dermatological 
preparations            
Corticosteroids, weak (Group I) D07AA02 Hydrocortisone acetate 1% 5       
Corticosteroids, potent (Group III) D07AC01 Bethametasone  1(2)       
D08 Antiseptics and disinfectants            
Iodine products D08AG02 Povidone-iodine 1       
Silver compounds D08AL01 Silver nitrate  1       
D09 Medicated dressings           
Soft parafin dressings D09AX 
S & N tulle gras dressings yellow 
soft parafin  1       
      43   7   
G. Genitourinary system and sex hormones 
G03 
Sex hormones and modulators of 
the genital system            
Gonadotrophins G03GA01 Human chorionic gonadotrophin 1 1   Not registered (1) 
G04 Urologicals           
Medicines used in erectile dysfunction G04BE03 Sildenafil 1 1 1 Extemporaneous (1) age (1) 
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      2 2 1   
H. Systemic hormonal preparations, excl sex hormones and insulin  
H01 
Pituatary and hypothalmic 
hormones and analogues           
Vasopressin and analogues H01BA02 Desmopressin 2   1 Dose (1)  
H02 Corticosteroids for sytemic use           
Glucocorticoids H02AB01 Bethametasone  1       
  H02AB02 Dexamethasone  7 2 3 
Not registered (2) Dose (1) 
indication (1) route (1)  
  H02AB04 Methlyprednisone  7   5 Dose (4) route (1) 
  H02AB06 Prednisone  52   14 Indication (9) Dose (5) 
  H02AB07 Prednisolone  3   2 Indication (2) 
  H02AB09 Hydrocortisone  2   2 Indication (1) dose (1) 
H03 Thyroid therapy           
Thyroid hormones H03AA01 Levothyroxine sodium  4       
H04 Pancreatic hormones           
Glycogenoltyic hormones H04AA01 Glucagon  1       
      79 2 27   
J. Anti-infectives for systemic use  
J01 
Anti-bacterials for systemic 
use           
Penicillins with extended spectrum J01CA01 Ampicillin  12   3 Dose (3) 
  J01CA04 Amoxicillin 14   1 Dose (1)  
Beta lactamase sensitive penicillins  J01CE01 Benyl Penicillin 2   1 Dose (1)  
Beta lactamase resistant penicillins  J01CF02 Cloxacillin 2       
  J01CF05 Flucloxacillin 1       
Combination of penicillins, including beta lactamase 
inhibitors  J01CR02 Amoxycillin/clavulanic acid 11   2 Dose (2)  
  J01CR05 Piperacillin with tazobactam 14   5 Dose (5) 
Second generation Cephalosporins J01DC02 Cefuroxamine 25   4 Dose( 4)  
Third generation cephalosporin J01DD01 Cefotaxime  9   4 Dose (4)  
  J01DD04 Ceftriaxone  18   14 Dose (14) 
Carbapenems J01DH02 Meropenem 11   3 Dose (2) age (1) 
 
J01DH03 Ertapenem 12   10 Dose (8) age (2) 
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Combination of sulphonamides and trimethoprim, incl. 
derivates  J01EE01 Co-trimoxazole  33   14 Dose (13) indication (1) 
Macrolides J01FA01 Erythromycin 4 1   Extemporaneous (1) 
  J01FA10 Azithromycin 3       
Other aminogycosides J01GB03 Gentamycin 19   13 
Dose (6) route (6) frequency 
(1) 
Other aminogycosides J01GB06 Amikacin 24   14 Dose (13) indication (1) 
Flouroquinolones J01MA01 Ofloxacin  15 15   Not registered (15) 
  J01MA02 Ciprofloxacin 1       
Glycopeptide antibacterials J01XA01 Vancomycin 9   4 Dose (3) age (1) 
Polymyxins J01XB01 Colistin 1 1   Not registered 
J02 Antimycotics for systemic use           
Antibiotics  J02AA01 Amphoterican B 1   1 Dose (1)  
Triazole derivative  J02AC01 Fluconazole  15   2 Dose (2)  
J04 Antimycobacterials            
Antibiotics  J04AB02 Rifampicin 31   2 Dose (1) age(1) 
Hydrazides J04AC01 Isoniazid 53 49 21 
Extemporaneous (49) dose 
(21)  
Thiocarbamide derivatives J04AD03 Ethionamide 25 24 2 
Extemporaneous (24) dose (1) 
age (1) 
Other Medicines for the treatment of tuberculosis  J04AK01 Pyrazinamide 36 34 7 
Extemporaneous (34) dose (5) 
age (2) 
  J04AK02 Ethambutol 28 27 2 
Extemporaneous (27) dose (1) 
age (1) 
  J04AK03 Terizidone  12 1 10 Extemproaneous (1) dose (10) 
Combinations of medicines for treatment of tuberculosis J04AM02 Rifampicin and Isoniazide 4   2 Dose (2)  
  J04AM05 
Rifampicin, 
Isoniazide,pyrazinamide 10 2 4 
Not registered (1) 
Extemporaneous (1)Dose (4) 
  J04AM06 
Rifampicin, 
isoniziazid,pyrazinamide and 
ethambutol 1   1 Age (1) 
Medicines for the treatment of lepra J04BA02 Dapsone 3 1 3 Extemproaneous (1) Dose (3)  
J05 Antivirals for systemic use           
Nucleoside and nucleotides excl. reverse transcriptase 
inhibitors J05AB01 Aciclovir 8   2 Dose (2) 
  J05AB06 Ganciclovir 7   2 Dose (1) frequency (1) 
  J05AB14 Valganciclovir  1       
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Protease Inhibitors J05AE03 Ritonavir 10 8 4 
Not registered (8) age (3) dose 
(1) 
Nucleoside and nucleotide reverse transcriptase inhibitors J05AF01 Zidovudine 1       
  J05AF04 Stavudine  5 1 5 
Extemporaneous (1) dose (4) 
age (1) 
  J05AF05 Lamivudine  26   20 Dose (20) 
  J05AF06 Abacavir 22   16 Dose (16) 
Non-nucleoside reverse transcriptase inhibitors J05AG01 Nevirapine  7   2 Dose (2) 
  J05AG03 Efavirenz  5   4 Dose (4) 
Antivirals for the treatment of HIV infections combinations of 
NTRIs/NNRTIs J05AR01 Zidovine and lamivudine  1   1 Dose (1) 
Antivirals for the treatment of HIV infections combinations of 
protease inhibitors J05AR10 Lopinovir-ritonavir 21   18 Dose (18)  
J06 
Immune sera and 
immunoglobulins            
Immunoglobulins, normal human  J06BA02 Intravenous Immunoglobulins 6   3 Dose (3)  
J07 Vaccines            
Pneumococcal vaccines  J07AL02 
Pneumococcus, purified 
polysaccharide antigen 
conjugated  1       
Hepatitis Vaccines  J07BC01 Hepatitis B Vaccine  1       
Bacterial and viral vaccines, combined J07CA06 DTaP-IPV/Hib 1       
      582 164 226   
L. Anti-neoplastic and immunomodulating agents  
L01 Antinoeplatic agents            
Nitrogen mustard analogues L01AA01 Cyclophosphamide 5   1 Dose (1) 
Folic acid analogues L01BA01 Methotrexate 4   2 Dose (1) indication (1) 
Purine anologues L01BB02 Mercaptopurine  1       
Pyrimidine analogues L01BC01 Cytarabine 10   4 
Lack of paediatric data (3) 
Indication (1) 
Vinca alkaloids and analogues L01CA02 Vincristine  9       
Podophyllotoxin derivates L01CB01 Etoposide 5 5   Not registered (5) 
Platinum comounds L01XA02 Carboplatin 2 2   Not registered (2) 
Other antineoplastic agents L01XX02 Asparginase 8       
  L01XX05 Hydroxyurea/hydroxycarbamide 1 1   Not registered (1) 
L04 Immunosupressants           
Tumor necrosis factor alpha inhibitors L04AB01 Etanercept 2       
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Interleukin inhibitors L04AC07 Tocilizumab 1   1 Dose (1) 
Other Immunosupressants L04AX02 Thalidomide 1 1   Not registered (1) 
  L04AX03 Methotrexate 4   2 Dose (1) indication (1) 
      53 9 10   
M. Musculoskelatal system 
M01 
Anti-inflammatory and anti-
rheumatic products            
Acetic acis derivatives and related substances M01AB05 Diclofenac 1       
Proprionic Acid Derivates  M01AE01 Brufen  16   7 Dose (6) age (1) 
M03 Muscle relaxants            
Other quaternaty ammonium compounds M03AC01 Pancuronium 2       
Other centrally acting agents M03BX01 Baclofen 2   1 Dose (1)  
MO4 Anti-gout preparations       
Preparations inhibiting uric acid production M04AA01 Allopurinol 1   1 Route (1) 
M05 
Medicines for the treatment of 
bone diseases           
Bisphosphonates M05BA03 Pamidronic Acid 3 3   Not registered (3) 
      25 3 9   
N. Nervous System 
N01 Anesthetics           
Other general anesthetics N01AX03 Ketamine  12   1 Dose (1) 
N02 Analgesics           
Natural opoid alkaloids N02AA01 Morphine  8 6   Extemporaneous (6) 
Other opoids N02AX01 Tilidine  16   2 Dose (1) frequency (1) 
Anilides N02BE01 Paracetamol 74 1 11 
Extemporaneous (1) dose (10) 
lack of paediatric data (1) 
Other anti migrane preparations N02CX02 Clonidine 6 6   
Not registered (4) 
extemporaneous (2) 
N03 Anti-epileptics           
Barbiturates and derivates  N03AA02 Phenobarbital 16       
Phenylpiperidine derivates N03AB02 Phenytoin 2       
Fatty Acid Derivates N03AG01 Valproic Acid 9   3 Dose (3) 
Benzodiazepine derivatives N03AE01 Clonazepam 5       
Carboxamide derivatives N03AF01 Carbamazepine  3       
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Other antiepileptics N03AX09 Lamotrigine  2   1 Dose (1)  
N05 Psycholeptics           
Phenothiazines with aliphatic side chains  N05AA01 Chlorpromazine  1 1 1 Extemporaneous (1) dose(1) 
Benzodiazepine derivatives N05BA01 Diazepam 17   7 
Dose (5) contra-indication (1) 
route(1) 
  N05BA06 Lorazepam 2   1 Dose (1) 
  N05BA09 Clobazam 2 2   Not registered (2) 
Diphenylmethane derivates  N05BB01 Hydroxyzine 1   1 Dose (1) 
Aldehydes and derivates N05CC01 Chloral Hydrate  3   3 Contra-indication (3) 
Benzodiazepine derivatives N05CD08 Midazolam 4   2 Indication (2) 
N06 Psychoanaleptics           
Selective seratonin reuptake inhibitors N06AB03 Fluoxetine  5 3 3 Extemporaneous (3) Dose (3)  
      188 19 36   
P. Anti-parasitic products, insecticides and repellents 
P01 Anti-protozoals           
Nitroimidazole derivatives P01AB01 Metranidazole 8   2 Dose (2) 
Aminoquinolones P01BA01 Cloroquine 2   2 Dose (2) 
P02 Anthelmintics           
Benzimidazole derivates P02CA01 Mebendazole 1       
  P02CA03 Albendazole 1   1 Age (1)  
P03 
Ectoparasites, incl. scabicides, 
insecticides and repellents            
Sulfur containing product P03AA04 Sulfiram 1       
Other ectoparasiticides, incl scabicides P03AX01 Benzyl benzoate 1   1 Age (1) 
      14   6   
R. Respiratory system 
RO1 Nasal Preparations            
Sympathomimetics, plain R01AA05 Oxymetazolin 6   1 Age (1) 
Corticosteroids R01AD01 Becloetasone  1       
other nasal preparations  R01AX10 Sodium Chloride 10 1 1 Not registered (1) dose (1) 
RO2 Throat preparations            
Antiseptics R02AA15 Povidone-iodine 1       
RO3 
Medicines for obstuctive 
airway disease           
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Alpha - and beta adrenoreceptor agonist R03AA01 Epinephrine  6   2 Age (1) dose (1) 
Selective Beta 2 adrenoreceptor agonists R03AC02 Salbutamol 5       
  R03AC04 Fenoterol 9   10 Age (6) dose (2) frequency (2) 
Glucocorticoids R03BA02 Budesonide 8       
Anticholinergics  R03BB01 Ipratropium Bromide 1   1 Age (1) 
RO6 
Anti-histamines for systemic 
use           
Piperazine derivatives R06AE07 Cetirizine 1       
Substituted alkylamines R06AB04 Chlorphenamine  1   1 Dose (1) 
      49 1 16   
S. Sensory Organs  
S01 Opthalmologicals            
Antibiotics  S01AA01 Chloramphenicol eye ointment  2   2 
Contraidication (1) lack of 
paediatric data (1) 
  S01AX11 Ofloxacin 3   1 Indication (1) 
Carbonic anhydrase inhibitors S01EC01 Acetazolomide 2       
Sympathomimmetics used as decongestants S01GA52 Tetryzoline with antazoline 1       
Visceoelastic Substances S01KA02 Hypromellose 1       
      9   3   
V. Various  
V03 All other therapeutic products           
Medicines for the treatment of hyperkalemia and 
hyperphosphatemia V03AE01 Polystyrene sulfonate  3       
Detoxifying agents for antineoplastic treatment V03AF03 Folinic Acid 1 1   Not registered (1) 
V04 Diagnostic agents            
Tests for diabetes V04CA02 Glucose 1       
Tests for pituitary function V04CD01 Metyrapone 3 3   Not registered (3) 
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Appendix 2: Anatomic Therapeutic Classification (ATC) classification of medicines as defined by the Delphi Survey(6) 
 




No. of UR 
events  
No. of OL 
events  Criterion for OL/UR use  
A. Alimentry tract and metabolism  
A01  Stomatological preparations            
Antiinfectives and antiseptics for local and 
systemic treatment  A01AB09 Clotrimazole  2   2 Extemporaneous (1) route (1) 
Corticosteroids for local oral treatment  A01AC01 Triamcinolone  1       
Other agents for oral treatment  A01AD02 Benzydamine 1       
A02  Medicines for acid related disorders            
H2 receptor antagonists  A02BA02 Ranitidine  1       
Proton pump inhibitors  A02BC01 Omperazole 14   16 
Extemporaneous (7) Dose (6) 
frequency (2) age (1) 
Other medicines for eptic ulcer and gastro-
oesophageal reflux disease A02BX02 Sucralfate 1 1   Not registered (1) 
A03 
Medicines for functional 
gastrointestinal disorders           
Propusives  A03FA01 Metoclopramide 3   1 Age (1) 
  A03FA03 Domperidone  1       
A04 Anit-emetics and anti-nauseants           
Sertaonin antagonists  A04AA01 Ondansetron 4   1 Dose (1) 
A06 Medicines for constipation           
Osmotically acting laxatives A06AD11 Lactulose 8   3 Dose (2) age (1)  
  A06AD17 Sodium Phosphate  1   1 Lack of paediatric data (1) 
Enemas  A06AG04 Glycerol 2   1 Lack of paediatric data (1) 
A07 
Anti-diarrheals, intestinal anti-
inflammatory.anti-infective agents            
Antibiotics  A07AA02 Nystatin  4       
A09 Digestives, include. Emzymes           
Emzyme preparations  A09AA02 Pancreatin  1   1 Extemporaneous (1)  
A10 Medicines used in diabetes            
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Insulins and analogues for injection, fast 
acting  A10AB01 Insulin  30       
Insulins and analogues for injection, ultra fast 
acting  A10AB05 Insulin 3       
Insulins and analogues for injection, 
intermediat acting  A10AC01 Insulin  32       
A11 Vitamins           
Multivitamins and other minerals, incl 
combinations  A11AA03 Multivitamin Syrup 80   1 Dose(1) 
Vitamin A Plain A11CA01 Retinol 4   1 Dose(1) 
Vitamin D analogues A11CC01 Ergocalciferol 15       
  A11CC03 Alphacalidiol 3       
  A11CC04 Calcitriol 1 1 1 Not registered (1) dose (1) 
Vitamin B1, Plain A11DA01 Thiamine  2   2 Dose (2)  
Vitamin B complex, plain A11EA Vitamin B complex 1       
Other plain vitmain preparations  A11HA02 Pyridoxine  14   3 Extemporaneous (2) dose (1) 
  A11HA03 Vitamin E 3   1 Dose (1) 
  A11HA05 Biotin 1   1 Extemporaneous (1) 
A12 Mineral Supplements           
Calcium A12AA01 Phosphate 11   11 Extemporaneous (11)  
  A12AA04 Calcium carbonate 10   1 Dose (1) 
Potassium A12BA01 Potassium chloride 16   18 
Extemporaneous (16) dose(1) 
age (1) 
Zinc A12CB02 Zinc gluconate  53   32 
Dose (29) indication (2) Lack of 
data (1) 
Magnesium A12CC01 Magnesium chloride 8   11 
Extemporaneous (8) lack of data 
(2) age (1) 
  A12CC02 Magnesium suphate  2 1   Not registered (1) 
      333 3 109   
B. Blood and blood forming organs  
B01 Anti-thrombotics           
Heparin group B01AB05 Enoxaparin sodium  1 1   Not registered (1) 
Platelet aggregaion inhibitors excl. heparin B01AC06 Asprin 1       
B02 Anti-haemorrhagics           
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 
 70 
Antifibrinolytics B02AA02 Tranexamic acid 3       
Vitamin K  B02BA01 Phytomenadione  8       
Blood coagulation factors  B02BD02 Factor 8 1       
B03 Anti-anemic preparations            
Iron bivalet, oral preparations  B03AA03 Ferrous lactate/salts  12 1 3 Extemporaneous (1) dose (2)  
Folic acid and derivates  B03BB01 Folic Acid 20   18  Extemporaneous (3) dose( 15) 
Other anti-anemic preparations  B03XA02 Epoetin  1       
B05 
Blood substitutes and perfusion 
solutions            
Blood substitutes and plasma protein fractions  B05AA01 Albumin 20% 1       
Salt solutions  B05CB04 Sodium bicarbonate  4 2 2 
Not registered (2) 
Extemporaneous (2) 
  B05XA03 Sodium chloride 5% 3       
      55 4 23   
C. Cardiovascular System  
C02 Antihypertensives            
Alph-adrenoreceptor antagonists  C02CA04 Doxazosin 1 1   Not registered (1) 
C03 Diuretics            
Low ceiling diuretics, thiazides plain C03AA03 Hydrochlorothiazide 1   1 Extemporaneous (1) 
Highceiling diuretics, sulponamides plain C03CA01 Furosemide 22   5 Extemporaneous (1) Dose(4)  
Aldosterone antagonists  C03DA01 Spironolactone  16   16 Extemporaneous (16) 
C07 Beta blocking agents            
Beta blocing agents, non selective  C07AA05 Propanolol 2       
Beta blocking agents,selective  C07AB03 Atenolol 5 5   Not registered (5) 
C08 Calcium channel blockers           
Dihydropyridine derivatives  C08CA01 Amlodipine  7 7   Not registered (7) 
  C08CA05 Nifedipine  1 1   Not registered (1) 
C09 
Agents acting on the rennin-
angiotensin system            
ACE inhibitors, plain C09AA01 Captopril 2 1 1 
Not registered (1) 
extemporaneous (1) 
  C09AA02 Enalapril 3 3 1 Not registered (3) indication(1)  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 
 71 
C10 Lipid modifying agents            
Bile sequatrants  A10AC01 Cholestyramine  7   7 Dose (7)  
      67 18 31   
D. Dermatologicals 
D01 Anti-fungals for dermatological use           
Antibiotics D01AA01 Nystatin 16   1 Lack of paediatric data (1) 
Antifungals for sytemic use D01BA01 Griesofulvin 2       
D02 Emmolients and protectives           
Zinc poducts  D02AB Zinc castor oil ointment  5   4 Lack of paediatric data (4) 
Soft paraffin and fat products  D02AC Aqueous cream  4       
    Haldens emulsifying base 3       
Carbamid products  D02AE51 Urea in emollient base  4   1 Lack of paediatric data (1) 
D06 
Anti-biotics and chemotherapeutics 
for dermatological use            
Anti-virals D06BB03 Aciclovir 1   1 Lack of paediatric data (1) 
D07 
Corticosteroid dermatological 
preparations            
Corticosteroids, weak (Group I) D07AA02 Hydrocortisone acetate 1% 5       
Corticosteroids, potent (Group III) D07AC01 Bethametasone  1(2)       
D08 Antiseptics and disinfectants            
Iodine products D08AG02 Povidone-iodine 1       
Silver compounds D08AL01 Silver nitrate  1       
D09 Medicated dressings           
Soft parafin dressings D09AX 
S & N tulle gras dressings yellow soft 
parafin  1       
      43   7   
G. Genitourinary system and sex hormones 
G03 
Sex hormones and modulators of the 
genital system            
Gonadotrophins G03GA01 Human chorionic gonadotrophin 1 1   Not registered (1) 
G04 Urologicals           
Medicines used in erectile dysfunction G04BE03 Sildenafil 1   2 Extemporaneous (1) age (1) 
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      2 1 2   
H. Systemic hormonal preparations, excl sex hormones and insulin  
H01 
Pituatary and hypothalmic hormones 
and analogues           
Vasopressin and analogues H01BA02 Desmopressin 2   1 Dose (1)  
H02 Corticosteroids for sytemic use           
Glucocorticoids H02AB01 Bethametasone  1       
  H02AB02 Dexamethasone  7 2 3 
Not registered (2) Dose (1) 
indication (1) route (1)  
  H02AB04 Methlyprednisone  7   5 Dose (4) route (1) 
  H02AB06 Prednisone  52   14 Indication (9) Dose (5) 
  H02AB07 Prednisolone  3   2 Indication (2) 
  H02AB09 Hydrocortisone  2   2 Indication (1) dose (1) 
H03 Thyroid therapy           
Thyroid hormones H03AA01 Levothyroxine sodium  4       
H04 Pancreatic hormones           
Glycogenoltyic hormones H04AA01 Glucagon  1       
      79 2 27   
J. Anti-infectives for systemic use  
J01 Anti-bacterials for systemic use           
Penicillins with extended spectrum J01CA01 Ampicillin  12   3 Dose (3) 
  J01CA04 Amoxicillin 14   1 Dose (1)  
Beta lactamase sensitive penicillins  J01CE01 Benyl Penicillin 2   1 Dose (1)  
Beta lactamase resistant penicillins  J01CF02 Cloxacillin 2       
  J01CF05 Flucloxacillin 1       
Combination of penicillins, including beta 
lactamase inhibitors  J01CR02 Amoxycillin/clavulanic acid 11   2 Dose (2)  
  J01CR05 Piperacillin with tazobactam 14   5 Dose (5) 
Second generation Cephalosporins J01DC02 Cefuroxamine 25   4 Dose(4)  
Third generation cephalosporin J01DD01 Cefotaxime  9   4 Dose (4)  
  J01DD04 Ceftriaxone  18   14 Dose (14) 
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Carbapenems J01DH02 Meropenem 11   3 Dose (2) age (1) 
 J01DH03 Ertapenem 12   10 Dose (8) age (2) 
Combination of sulphonamides and 
trimethoprim, incl. derivates  J01EE01 Co-trimoxazole  33   14 Dose (13) indication (1) 
Macrolides J01FA01 Erythromycin 4   1 Extemporaneous (1) 
  J01FA10 Azithromycin 3       
Other aminogycosides J01GB03 Gentamycin 19   13 Dose (6) route (6) frequency (1) 
Other aminogycosides J01GB06 Amikacin 24   14 Dose(13) indication(1) 
Flouroquinolones J01MA01 Ofloxacin  15 15   Not registered (15) 
  J01MA02 Ciprofloxacin 1       
Glycopeptide antibacterials J01XA01 Vancomycin 9   4 Dose (3) age (1) 
Polymyxins J01XB01 Colistin 1 1   Not registered 
J02 Antimycotics for systemic use           
Antibiotics  J02AA01 Amphoterican B 1   1 Dose (1)  
Triazole derivative  J02AC01 Fluconazole  15   2 Dose (2)  
J04 Antimycobacterials            
Antibiotics  J04AB02 Rifampicin 31   2 Dose (1) age(1) 
Hydrazides J04AC01 Isoniazid 53   70 Extemporaneous (49) dose (21)  
Thiocarbamide derivatives J04AD03 Ethionamide 25   26 
Extemporaneous (24) dose (1) 
age (1) 
Other Medicines for the treatment of 
tuberculosis  J04AK01 Pyrazinamide 36   41 
Extemporaneous (34) dose (5) 
age (2) 
  J04AK02 Ethambutol 28   29 
Extemporaneous (27) dose (1) 
age (1) 
  J04AK03 Terizidone  12   11 Extemproaneous (1) dose (10) 
Combinations of medicines for treatment of 
tuberculosis J04AM02 Rifampicin and Isoniazide 4   2 Dose (2)  
  J04AM05 Rifampicin, Isoniazide,pyrazinamide 10   5 
Not registered (1) 
Extemporaneous (1)Dose (4) 
  J04AM06 
Rifampicin, isoniziazid,pyrazinamide and 
ethambutol 1   1 Age (1) 
Medicines for the treatment of lepra J04BA02 Dapsone 3   4 Extemporaneous (1) Dose (3)  
J05 Antivirals for systemic use           
Nucleoside and nucleotides excl. reverse 
transcriptase inhibitors J05AB01 Aciclovir 8   2 Dose (2) 
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  J05AB06 Ganciclovir 7   2 Dose (1) frequency (1) 
  J05AB14 Valganciclovir  1       
Protease Inhibitors J05AE03 Ritonavir 10 8 4 
Not registered (8) age (3) dose 
(1) 
Nucleoside and nucleotide reverse 
transcriptase inhibitors J05AF01 Zidovudine 1       
  J05AF04 Stavudine  5   6 
Extemporaneous (1) dose (4) age 
(1) 
  J05AF05 Lamivudine  26   20 Dose (20) 
  J05AF06 Abacavir 22   16 Dose (16) 
Non-nucleoside reverse transcriptase 
inhibitors J05AG01 Nevirapine  7   2 Dose (2) 
  J05AG03 Efavirenz  5   4 Dose (4) 
Antivirals for the treatment of HIV infections 
combinations of NTRIs/NNRTIs J05AR01 Zidovine and lamivudine  1   1 Dose (1) 
Antivirals for the treatment of HIV infections 
combinations of protease inhibitors J05AR10 Lopinovir-ritonavir 21   18 Dose (18)  
J06 Immune sera and immunoglobulins            
Immunoglobulins, normal human  J06BA02 Intravenous Immunoglobulins 6   3 Dose (3)  
J07 Vaccines            
Pneumococcal vaccines  J07AL02 
Pneumococcus, purified polysaccharide 
antigen conjugated  1       
Hepatitis Vaccines  J07BC01 Hepatitis B Vaccine  1       
Bacterial and viral vaccines, combined J07CA06 DTaP-IPV/Hib 1       
      582 24 365   
L. Anti-neoplastic and immunomodulating agents  
L01 Antinoeplatic agents            
Nitrogen mustard analogues L01AA01 Cyclophosphamide 5   1 Dose (1) 
Folic acid analogues L01BA01 Methotrexate 4   2 Dose (1) indication (1) 
Purine anologues L01BB02 Mercaptopurine  1       
Pyrimidine analogues L01BC01 Cytarabine 10   4 
Lack of paediatric data (3) 
Indication (1) 
Vinca alkaloids and analogues L01CA02 Vincristine  9       
Podophyllotoxin derivates L01CB01 Etoposide 5 5   Not registered (5) 
Platinum comounds L01XA02 Carboplatin 2 2   Not registered (2) 
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Other antineoplastic agents L01XX02 Asparginase 8       
  L01XX05 Hydroxyurea/hydroxycarbamide 1 1   Not registered (1) 
L04 Immunosupressants           
Tumor necrosis factor alpha inhibitors L04AB01 Etanercept 2       
Interleukin inhibitors L04AC07 Tocilizumab 1   1 Dose (1) 
Other Immunosupressants L04AX02 Thalidomide 1 1   Not registered (1) 
  L04AX03 Methotrexate 4   2 Dose (1) indication (1) 
      53 9 10   
M. Musculoskelatal system 
M01 
Anti-inflammatory and anti-rheumatic 
products            
Acetic acis derivatives and related substances M01AB05 Diclofenac 1       
Proprionic Acid Derivates  M01AE01 Brufen  16   7 Dose (6) age (1) 
M03 Muscle relaxants            
Other quaternaty ammonium compounds M03AC01 Pancuronium 2       
Other centrally acting agents M03BX01 Baclofen 2   1 Dose (1)  
MO4 Anti-gout preparations       
Preparations inhibiting uric acid production M04AA01 Allopurinol 1   1 Route (1) 
M05 
Medicines for the treatment of bone 
diseases           
Bisphosphonates M05BA03 Pamidronic Acid 3 3   Not registered (3) 
      25 3 9   
N. Nervous System 
N01 Anesthetics           
Other general anesthetics N01AX03 Ketamine  12   1 Dose (1) 
N02 Analgesics           
Natural opoid alkaloids N02AA01 Morphine  8   6 Extemporaneous (6) 
Other opoids N02AX01 Tilidine  16   2 Dose (1) frequency (1) 
Anilides N02BE01 Paracetamol 74   12 
Extemporaneous (1) dose (10) 
lack of paediatric data (1) 
Other anti migrane preparations N02CX02 Clonidine 6 4 2 
Not registered (4) 
extemporaneous (2) 
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N03 Anti-epileptics           
Barbiturates and derivates  N03AA02 Phenobarbital 16       
Phenylpiperidine derivates N03AB02 Phenytoin 2       
Fatty Acid Derivates N03AG01 Valproic Acid 9   3 Dose (3) 
Benzodiazepine derivatives N03AE01 Clonazepam 5       
Carboxamide derivatives N03AF01 Carbamazepine  3       
Other antiepileptics N03AX09 Lamotrigine  2   1 Dose (1)  
N05 Psycholeptics           
Phenothiazines with aliphatic side chains  N05AA01 Chlorpromazine  1   2 Extemporaneous (1) dose(1) 
Benzodiazepine derivatives N05BA01 Diazepam 17   7 
Dose (5) contra-indication (1) 
route (1) 
  N05BA06 Lorazepam 2   1 Dose (1) 
  N05BA09 Clobazam 2 2   Not registered (2) 
Diphenylmethane derivates  N05BB01 Hydroxyzine 1   1 Dose (1) 
Aldehydes and derivates N05CC01 Chloral Hydrate  3   3 Contra-indication (3) 
Benzodiazepine derivatives N05CD08 Midazolam 4   2 Indication (2) 
N06 Psychoanaleptics           
Selective seratonin reuptake inhibitors N06AB03 Fluoxetine  5   6 Extemporaneous (3) Dose (3)  
      188 6 49   
P. Anti-parasitic products, insecticides and repellents 
P01 Anti-protozoals           
Nitroimidazole derivatives P01AB01 Metranidazole 8   2 Dose (2) 
Aminoquinolones P01BA01 Cloroquine 2   2 Dose (2) 
P02 Anthelmintics           
Benzimidazole derivates P02CA01 Mebendazole 1       
  P02CA03 Albendazole 1   1 Age (1)  
P03 
Ectoparasites, incl. scabicides, 
insecticides and repellents            
Sulfur containing product P03AA04 Sulfiram 1       
Other ectoparasiticides, incl scabicides P03AX01 Benzyl benzoate 1   1 Age (1) 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 
 77 
      14   6   
R. Respiratory system 
RO1 Nasal Preparations            
Sympathomimetics, plain R01AA05 Oxymetazolin 6   1 Age (1) 
Corticosteroids R01AD01 Becloetasone  1       
other nasal preparations  R01AX10 Sodium Chloride 10 1 1 Not registered (1) dose (1) 
RO2 Throat preparations            
Antiseptics R02AA15 Povidone-iodine 1       
RO3 
Medicines for obstuctive airway 
disease           
Alpha - and beta adrenoreceptor agonist R03AA01 Epinephrine  6   2 Age (1) dose (1) 
Selective Beta 2 adrenoreceptor agonists R03AC02 Salbutamol 5       
  R03AC04 Fenoterol 9   10 Age (6) dose (2) frequency (2) 
Glucocorticoids R03BA02 Budesonide 8       
Anticholinergics  R03BB01 Ipratropium Bromide 1   1 Age (1) 
RO6 Anti-histamines for systemic use           
Piperazine derivatives R06AE07 Cetirizine 1       
Substituted alkylamines R06AB04 Chlorphenamine  1   1 Dose (1) 
      49 1 16   
S. Sensory Organs  
S01 Opthalmologicals            
Antibiotics  S01AA01 Chloramphenicol eye ointment  2   2 
Contraindication (1) lack of 
paediatric data (1) 
  S01AX11 Ofloxacin 3   1 Indication (1) 
Carbonic anhydrase inhibitors S01EC01 Acetazolomide 2       
Sympathomimmetics used as decongestants S01GA52 Tetryzoline with antazoline 1       
Visceoelastic Substances S01KA02 Hypromellose 1       
      9   3   
V. Various  
V03 All other therapeutic products           
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Medicines for the treatment of hyperkalemia 
and hyperphosphatemia V03AE01 Polystyrene sulfonate  3       
Detoxifying agents for antineoplastic 
treatment V03AF03 Folinic Acid 1 1   Not registered (1) 
V04 Diagnostic agents            
Tests for diabetes V04CA02 Glucose 1       
Tests for pituitary function V04CD01 Metyrapone 3 3   Not registered (3) 
      8 4     
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